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ABSTRACT 
 
Vitamin D3 (D3) may impact ALS, a motoneurodegenerative disease. The study 
analyzed D3 supplementation at 50x the adequate intake (AI) and restriction at 2.5% the 
AI in the spinal cord of transgenic G93A, a mouse model of ALS. At 25 d, mice were 
provided food ad libitum with adequate (AI;1 IU D3/g feed), high (HiD; 50 IU D3/g 
feed) or deficient (DEF; 0.025 IU D3/g feed) D3. At 113 d, the spinal cords underwent 
protein analysis. HiD females exhibited D3 toxicity, evidenced by increased oxidative 
damage and apoptosis and lower antioxidant capacity vs. AI. HiD males exhibited lower 
oxidative damage, inflammation, apoptosis and neuron damage vs. AI. DEF females 
exhibited higher inflammation and a compensatory increase in GPx1 vs. AI. DEF males 
exhibited higher lipid peroxidation and lower antioxidant capacity vs. AI. In G93A mice, 
non-toxic doses of D3 attenuate disease pathophysiology, whereas deficiency worsens it 
in a sex-specific manner. 
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THESIS OVERVIEW 
 
The thesis that you are about to read is comprised of 2 manuscripts that will be submitted 
to peer-reviewed scientific journals and completed as part of my MSc degree. 
 
Manuscript #1: 
The first manuscript is a pilot study investigating the effects of vitamin D3 
supplementation (50 fold the adequate intake vs. the adequate intake) in the spinal cord of 
the G93A mouse model of ALS on disease pathophysiology. In addition, we investigated 
the effect of high vitamin D3 supplementation on the established sexual dichotomy in this 
animal model of ALS. 
 
Manuscript #2: 
The second manuscript is a pilot study investigating the effects of vitamin D restriction 
(1/40th the adequate intake vs. the adequate intake) in the spinal cord of the G93A mouse 
model of ALS on disease pathophysiology. In addition, we investigated the effect of 
vitamin D restriction on the established sexual dichotomy in this animal model of ALS.  
 1 
INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s and motor 
neuron disease (UK), is a chronic, progressive and fatal neurodegenerative disease, first 
described by Charcot in 1874 (1).  Though age of diagnosis can vary, ALS is typically a 
late-onset disease with diagnosis usually occurring between the ages of 45 and 60 years 
(2, 3). It is the most commonly occurring adult-onset motor neuron disease of unknown 
cause (4, 5). It is characterized by “amyotrophy” and “lateral sclerosis”. “Amyotrophy” 
or muscle wasting is due to denervation of muscle fibers as a result of motor neuron 
degeneration (6). “Lateral sclerosis” refers to the hardening of ventral and lateral 
corticospinal tracts, areas progressively replaced by gliosis (the reaction to damage in the 
central nervous system, involving proliferation and hypertrophy of neuroglia at sites of 
damage) (6). The corticomotoneuronal system, which includes the corticomotorneurons 
in the motor cortex and motor neurons in the brain stem and spinal cord, is the central 
target of the disease (7). The lifetime risk of developing the disease is 1 in 2000 (1).  ALS 
has an average incidence and prevalence rate of 1-2 cases per 100 000/year and 6 cases 
per 100 000/year respectively (5, 8). These rates are for the most part uniform throughout 
North America but can vary depending on geographic location, exclusion and inclusion 
criteria, statistical methodology and epidemiological studies (5). In recent decades, 
studies have noted an increase in prevalence rates, most likely a result of improved 
quality of care (9). Incidence rates are higher in the western pacific, including Guam 
Island and Japan (10).  The occurrence of the disease is higher in males vs. females with 
a ratio of 1.6:1 (8). This is especially observed in Europe and the United States (11). The 
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exact time of biological onset is unknown but it is hypothesized that the disease may 
manifest itself early in life and then become clinically apparent in later stages (2).   
Currently, the only available therapy for ALS is riluzole, an antiglutamatergic 
drug. 100 mg oral consumption of the drug may extend life for approximately 2-3 months 
and may increase the likelihood of survival in the first year by 9% (12). However, 
riluzole is a very expensive drug and costs approximately $10,000/year in the US and 
£4056/year in the UK.  
Etiology  
Progressive degeneration of upper motor neurons (UMN: run from motor cortex 
in the brain to the spinal cord) and lower motor neurons (LMN: run from spinal cord and 
brainstem and extend out to muscles) eventually lead to muscular weakness and atrophy, 
fasciculation, spasticity and paralysis (2, 13). The most commonly described pathological 
feature of ALS has been the degeneration and atrophy of the large motor neurons in the 
anterior horn of the spinal cord (14). There is selective atrophy of motor neurons where 
those that control eye movement and the bladder (i.e. Onuf’s nucleus located in the sacral 
cord) are, for the most part, not affected (1). It is not well understood exactly why motor 
neurons are the most vulnerable targets of the disease. They are the largest cells in the 
central nervous system and possess extremely long axons (>104 times larger than its cell 
body)  (14) where 99.9% of the radial growth of its cell volume resides (15). These cells 
require a robust cytoskeleton, high amounts of neurofilament protein and a high 
metabolic rate, which can make them susceptible to a plethora of insults (16).  
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How motor neuron degeneration occurs is currently unknown, but it is believed to 
result from a multitude of factors, including oxidative stress, glutamate excitotoxicity, 
protein misfolding and aggregation, abnormal protein secretion, mitochondrial 
dysfunction, reduced neurotrophic factor secretion, ruptures in axonal passage and 
dysregulated calcium metabolism (3, 17). In its primary stage, axon connections start to 
break down and retract, no longer innervating LMN and muscle which initiates the start 
of symptoms and disease progression (2). Initially, more resistant neurons can 
compensate for this degenerative effect via axonal sprouting and collateral re-innervation 
(18). As the disease progresses, this compensational mechanism fails and neuronal cell 
bodies become abnormal, resulting in neuronal atrophy, as observed in animal models (2, 
18-20). Such abnormalities include reactive gliosis, intracytoplasmic neurofilament 
abnormalities and axonal spheroids (1). Axonal spheroids are comprised of large 
eosinophilic and argentophilic masses that form at the initial segment of lower motor 
neuron axons, representative of the early stages of ALS disease progression (14). Exactly 
when this cascade of events occurs in human ALS patients is unknown, but it is observed 
in rare post-mortem studies on patients who have died very early on in the disease(20).  
With the lack of neural guidance and a breakdown of neuromuscular junctions, 
skeletal muscle becomes denervated and is unable to acquire the signals needed to initiate 
movement. This results in a reduction in muscle mass, fibres (including fibre diameter) 
and force (9, 21), and spontaneous uncoordinated muscle activity (22). Muscle atrophy is 
first observed in proximal limbs or body region, and, over time with progression of the 
disease, spreads to distal muscles (23). A gradient loss of motor neurons is observed from 
the area of disease onset (24). 
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Ultimately, denervation of the diaphragm results in alveolar hypoventilation 
leading to death by respiratory failure within 3-5 years of initial symptoms (25-27). 50% 
of patients die within 30 months post-symptom onset and another 20% survive 5-10 years 
post-symptom onset (28). Usually, the patient will slip into a coma due to increased 
hypercapnia prior to death (8). There is a large variability in disease duration amongst 
patients which ranges from months to approximately two decades (2). ALS patients who 
are members of the same family and have the same genetic mutation can experience large 
differences in disease duration and age of onset, suggesting there are external factors 
modulating phenotypic outcomes (29). 
Environmental risk factors 
 There are multiple environmental risk factors proposed for ALS, most having to 
do with physical and toxic risk factors (8).  
Many epidiomiological studies have shown a multitude of risk factors attributed 
to ALS.  Education attainment has been associated with lower odds of ALS (30). This 
may likely be due to an increased awareness to work and live in environments with lower 
toxic exposure. Though studies have been mixed, cigarette smoking may be considered 
an established risk factor of sALS (31), a prospective study in the US reported elevated 
ALS risk with formaldehyde (a component of cigarettes) exposure among current female 
smokers compared to never smokers (RR = 1.67, 95% CI = 1.24-2.24, P = 0.002) (32). 
There is an elevated risk of ALS diagnosis in specific cohorts of people. Lifetime 
of intensive sport or physical exertion has been observed as a potential risk factor 
possibly due to an increased exposure and transport of the toxins, and heightened 
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susceptibility of target cells to toxic damage (33, 34). Many studies have shown no 
association between ALS and physical activity (32) but the results remain inconclusive.  
Military personnel who have active participation in the US armed forces have also been 
observed as a risk group (35). As well, a retrospective study of soccer players from the 
Italian professional leagues showed an increase in standardized morbidity ratios for the 
development of ALS, in particular younger-onset disease (36). Soccer players, 
particularly those in the active midfield position for more than five years were at the 
highest risk of developing ALS (36). As well, ALS has been diagnosed in a cluster of 
amateur English soccer players (37). 
Human and murine viruses and prion diseases are also being investigated as 
possible initiators of the disease (11, 13). It is believed that constant viral infections 
might cause sALS (13). In the 1983 study by Salazar et al., of the 33 ALS patients with 
dementia tested, 3 patients with “atypical” features compatible with ALS characteristics 
were able to transmit the disease to monkeys via brain tissue injection (38). The atypical 
features coincided with features of amyotrophy found in patients with Creutzfeldt-Jakob 
disease (38). As well, 50 cases of proven prion disease have shown LMN signs (38).  
Toxins may also play a role in the genesis of the disease. It has been suggested 
that the reason for elevated levels in the western pacific, particularly Guam, has to do 
with the presence of the neurotoxin β-methyl-amino-L-alanine (BMAA) in cycad tissue 
(39). Of cyanobacterial origin, this toxin bioaccumulates as it travels higher in the food 
chain (39). BMAA has the ability to pass the blood-brain barrier and many hypotheses 
have been proposed to explain its toxic action. Chronic ingestion of BMAA may cause it 
to become integrated in nerve cells and protein structure, altering it and causing it to 
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malfunction and aggregate, ultimately leading to death (40). BMAA may also be 
wrongfully integrated into proteins, particularly in place of serine (41). This is important, 
as serine plays an important role in phosphorylating protein sites and altering this process 
is a known mechanism in the pathogenesis of neurodegenerative diseases. Inhabitants of 
Guam Island, the Chamorro population, have a traditional diet that includes the fruit bat, 
which feeds on cycad seeds and thus bioaccumulates BMAA. Guamanian ALS patients 
have been shown to have a significant concentration of this neurotoxic amino acid in their 
brains (39).  
Free-radical-mediated mechanisms are also a possible cause of 
neurodegeneration. The ALS spinal cord has increased levels of selenium and manganese 
(42, 43). Manganese can inhibit neurotransmission (44), and high levels have been 
observed in Guam’s soil (45).  
Many chemicals have been associated with higher ALS risk with the strongest 
evidence coming from agricultural pesticides, fertilizers, herbicides and insecticides. 
There is an association between fertilizer exposure and ALS (32, 46). After adjusting for 
education, smoking and other occupational exposures such as metals, solvents and 
electromagnetic fields, a significant association was found between occupational 
exposure to pesticides and ALS (OR = 6.50, 95% CI = 1.78-23.77) (47). A systematic 
review confirmed a significant association between pesticide exposure and ALS (48). The 
harsh effects of these chemicals in ALS patients may be due to a group of proteins known 
as paraoxonases. Paraoxonase 1 in particular allows the body to eliminate toxins such as 
organophosphates. Compared to the general population, ALS patients are often carriers of 
certain variants of the genes, possibly reducing the detoxification effects of the protein.  
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In contrast to previous smaller studies showing an association,, a genetic meta-analysis of 
the literature has shown insignificant evidence (49). The challenge with meta-analyses is 
the pooling of different publications, thus disregarding differences between populations.  
Classification of ALS 
There are multiple classification systems for ALS (50). The simplest and most 
widely used classification is based on the localization of disease onset, which is a known 
predictor of disease progression (5). They are, bulbar-onset (25% of cases) and spinal 
onset (75% of cases), categorized according to the primary region of upper or lower 
motor neuron degeneration (5, 50). Bulbar onset, having a shorter survival time, initially 
affects the tongue, throat and lip muscles and progresses into dysarthria (slurred speech) 
and dysphagia (difficulty swallowing) (8, 51, 52). Spinal onset initially affects limb and 
trunk muscles resulting in muscle weakness, paralysis and atrophy, fasciculations and 
cramps (51, 52).  
Diagnosis 
In the late 1980s, the EI Escorial diagnostic criteria for ALS was developed (and 
subsequently revised) which provides a structured way to objectively assess patients who 
may have ALS (53, 54). It utilizes a combination of UMN and LMN signs in order to 
administer a score of diagnostic certainty (55). Scores are divided into 5 main categories: 
definite (LMN and UMN signs in three regions), probable (LMN and UMN signs in two 
regions), probable with laboratory support (LMN and UMN signs in one region or UMN 
signs in one or more regions with electromyography indicating acute muscle denervation 
in two or more limbs), possible (LMN and UMN signs in one region) and suspected 
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(LMN signs only in one or more regions or UMN signs only in one or more regions) (53). 
All categories must show that the sensory signs are not comorbid with other diseases and 
disease progression should be visible (54). Currently, the most widely used rating scale in 
clinical trials is the amyotrophic lateral sclerosis functional rating scale (ALSFRS), which 
records disease progression in patients and evaluates functional status and change (56).  
Subtypes of ALS 
ALS patients can be classified into two clinically indistinguishable subtypes: 
familial and sporadic. Familial ALS (fALS) undergoes Mendelian inheritance patterns, 
high penetrance and in almost all cases is autosomal dominant (X-linked or recessive 
types are extremely rare) (2, 17). It occurs in approximately 5%-10% of cases with ~12% 
of these cases being a result of a mutation in the Cu2+/Zn2+ super-oxide dismutase 1 
(SOD1) gene (1, 57-59). Currently, there are variants of approximately 30 gene mutations 
that are known to cause ALS in humans (60, 61) with the most notable ones being 
TARDBP, C9ORF72 and FUS/TLS (17). Sporadic ALS (sALS) is a more common form 
occurring in approximately 90% of patients, and is diagnosed in patients who do not have 
family members with the disease and thus do not fall under fALS (2, 62). This is not to 
say that a genetic component is not present in sALS, however there has been limited 
success in finding sALS-associated gene mutations (17). 1% of SALS cases can be 
explained by a mutation in the SOD1 gene (59). Epidemiological and pathophysiological 
mechanisms in sALS can be understood by investigating familial forms because of the 
clinical and pathological similarity between the two (17).   
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Superoxide dismutase 1 (SOD1) and its mutation 
 Copper/zinc superoxide dismutase (SOD1) was discovered in 1993 as the first 
ALS gene (57). It is one of three isoforms of superoxide dismutases in mammalian cells 
that are responsible for the conversion of superoxide (O2•-) to hydrogen peroxide (H2O2) 
(63). Mutation in SOD1 is recognized as the major genetic cause of ALS (17). The SOD1 
protein is a ubiquitous homodimer (64-66), and its gene consists of 153 codons on 
chromosome 21q22.1 and possibly 21q22.2 (67). The majority of the protein has an 
eight-strand beta-barrel conformation and is one of the most stable proteins known due to 
its extensive hydrogen bonding along the peptide backbone. Its cofactors are zinc and 
copper. SOD1 is mostly found in the motor neurons and glial cells of the spinal cord (64-
66), specifically the cytosol (in peroxisomes) as well as the intermitochondrial membrane 
space (68).  
The most important function of SOD1 is that it converts superoxide (O2•-: a toxic 
one-electron reduced by-product of mitochondrial oxidative phosphorylation) to water 
and hydrogen peroxide (H2O2) (69).  As an oxidizing agent, H2O2 has a very low 
reactivity and can impair cellular structures directly or combine with iron or copper ions 
to generate •OH, a potent free radical. Spinal motor neurons, which are the primary 
targets of ALS, are very sensitive to H2O2 and go through apoptosis when exposed to it in 
primary culture (70).   
SOD1 clears superoxide rapidly from the cell, even if the antioxidant enzyme’s 
levels are reduced by 50% (71). Superoxide is produced in vivo via the catalyzed one 
electron reduction of molecular oxygen through different biological systems including 
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mitochondrial electron transport chain, NADPH oxidases, and xanthine oxidase (72). 
Mediation of the catalysis of superoxide by SOD1 is in two asymmetric steps that require 
a copper atom in order to occur which becomes alternately reduced and oxidized by 
superoxide (69). Superoxide is found to be made largely in the mitochondrial matrix (73, 
74), and has also been found in the intermembrane space(68), areas in which the 
superoxide dismutase family has also been found.  
SOD1 is a very stable protein, and when bound to its cofactors (holo state) it can 
retain its activity in 6 M urea and survive heating to 80˚C (75). However, in the apo state 
when both metals are missing, the protein denatures at a faster rate. Thus, it is mutations 
affecting the protein’s binding to its cofactors that make it more susceptible to 
denaturation and aggregation. The main consequence mutations have on these proteins is 
that they destabilize their overall structure. This was confirmed by Bosco et al who 
showed that an important underlying factor of both fALS and sALS may be a misfolding 
both in wild-type as well as mutant SOD1 giving it a disease-specific and toxic profile 
(76). Assays of SOD1 activity in extracts from red blood cells, brain tissues and 
lymphoblastoid cells revealed ~50% reduction in fALS patients when compared to 
normal controls (77), indicating that lower SOD1 activity can induce pathways leading to 
oxidative damage and thus fALS symptoms.   
 There are currently 160 recorded mutations in the SOD1 gene that can result in 
ALS with a majority being missense, where one residue is substituted with another 
(nonsense and deletion are rare) (50). Some amino acid sites can have as many as six 
different substitutions. More than 90 of the 160 mutations have 40 out of the 153 amino 
acid residues involved (13). These mutations are found within the primary and three-
 11 
dimensional protein structure (69). The majority is found scattered throughout the protein 
in key areas of the dimer interface, active site and beta barrel  (78). Despite the fact that 
the overall distribution of mutation sites is random, the majority of the mutations affect 
side chains facing inside the hydrophobic interior of the protein or within the dimer 
interface.  
All SOD1 mutations are dominant except for D90A (an aspartate is exchanged for 
an alanine at position 90), which can be recessive  (79) or dominant  (80). The most 
common SOD1 mutation is A4V (alanine is exchanged for valine at position 4) (13). It 
has one of the fastest progressing forms of ALS, with survival under 1 year post 
diagnosis  (81). The type of SOD1 mutation can dictate many characteristics of the 
disease such as age of onset, survival and clinical classification (i.e. bulbar or spinal) 
(13).  
Mutations in the gene cause the antioxidant to gain a toxic function independent 
of the levels of SOD1 activity (69) that leads to MND (50). SOD1 not only has a 
dismutation function but it also has a peroxidative function whereby H2O2 and anionic 
radical scavengers such as glutatmate are used as substrates to produce free radicals such 
as OH (82). In G93A mice, both WT and mSOD1 have dismutation activities (though 
mSOD1 has 93% of WT dismutation activity). What differs between the two is that the 
free-radical generating function is enhanced in mSOD1 relative to WT  (82). This is due 
to H2O2 in mSOD1 having lower Km ( i.e. higher affinity) compared to WT. The lower 
Km value may be a result of mutations that destabilize the β barrel backbone of the 
enzyme which opens the active channel causing a higher accessibility of H2O2 to the 
active site, resulting in lower Km and thus elevated production of OH. In both ALS 
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patients and G93A mice, the presence of elevated glutamate levels raises the 
concentration of glutamate-derived free radicals which damage glutamate transport 
machinery and receptors  (77) 
 Although SOD1 is found in the cytosol of the cell, its mutant form becomes 
colocalized with the mitochondria in the CNS and generates free radicals, yet it still 
maintains the dismutation function found in normal human SOD1 (83). In mice that 
develop MND, removal of normal SOD1 genes in order to inhibit the expression of a 
dismutase inactive mutant (SOD1G85R) has no effect on onset or survival  (84). Pathology 
in SOD1 mice is non-cell autonomous. This means motor neuron death and degeneration 
and the associated neurological symptoms require mSOD1 expression in other cells in 
addition to neurons, such as glia to initiate neuron toxicity, degeneration and death  (85-
87).   
In ALS profiles, mutated SOD1 becomes involved in oxidative stress, 
excitotoxicity, mitochondrial dysfunction, neuroinflammation, endosomal trafficking, 
axonopathy and apoptosis  (50, 88). The exact mechanism of toxicity that SOD1 utilizes 
to cause neurodegeneration is currently unknown (17, 69). There is a general consensus 
that mutations in SOD1 structurally weaken the antioxidant enzyme to form a partially 
unfolded intermediate  (89). According to a multitude of studies, the first step in 
unfolding of SOD1 is due to the loss of the structural zinc atom as SOD1 has a naturally 
modestly reduced affinity for the metal  (89). A loss in zinc causes SOD1 to become 
more accessible, more redox reactive and a better catalyst for tyrosine nitration  (89). As 
well, aggregation of the protein occurs after loss of its metals, with zinc most likely to be 
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lost first as it is bound 7000 times more weakly than copper  (90). As is the case in 
mSOD1, loss of zinc is equally toxic in WT SOD1 to motor neurons  (91).  
A loss of zinc from SOD1 causes a partial disorganization in portions of the 
SOD1 protein which protect the attached copper causing it to become extremely toxic to 
motor neurons via a mechanism requiring nitric oxide  (89). Zinc itself is not involved in 
the catalytic dismutation of superoxide, but instead provides the structural support for the 
active site. The redox properties of SOD1 are significantly altered with the loss of zinc. It 
has been postulated that the loss of zinc can cause the remaining copper to be more 
accessible to intracellular reductants by disordering the two largest loops that normally 
restrict access of copper to only superoxide  (78).  The reduced copper can be reoxidized 
by molecular oxygen to produce superoxide and could continue to be in a reduced state in 
the CNS as a result of the high concentrations of ascorbate, a reducing agent (millimolar 
in concentration and highest in the body). It is important to note that mutant SOD1 that 
was carefully purified to contain both the zinc and copper cofactors was just as protective 
as WT SOD1 to motor neurons deprived of neurotrophic factors  (91).  
Mouse models of ALS 
Though ALS is not a naturally occurring disease in mice (Mus musculus), 
manipulation of their genome can give rise to this disease and thus allow it to be studied. 
Transgenic mice that ubiquitously overexpress different mSOD1 genes at levels equal to 
or several folds higher than endogenous SOD1 levels (1) adopt a neurodegenerative 
profile that follows the same pathology and outcome as the human disease (17). 
However, in transgenic mice that overexpress WT human SOD1 or mutant SOD1 only in 
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neurons and glial cells, the disease does not develop  (84, 86, 92). Currently it is 
unknown exactly why the SOD1 gene has to be expressed ubiquitously in order to induce 
targeted damage to the motor neurons. Virtually all studies that have used mouse models 
use endogenous murine SOD1 promoter that causes overexpression of the mutant SOD1 
gene to be present in all tissues (17).  
In mouse models, overexpression of either G37R, G85R, G86R, D90A, G93A, 
H46R/H48Q or H45R/H48Q/H63G/H120G, L126Z and G127X mutant SOD1 protein 
leads to motor neuron degeneration in the spinal cord and myelinated axons in the ventral 
motor roots (17).  
Of the different mutations, G93A is the most widely used model in research 
where an alanine substitutes a glycine at codon 93  (93). In 1994, Gurney et al were 
successful in producing the first SOD1G93A mouse line [Tg(SOD1*G93A)1GUR] in 
which the cDNA of a human mutant SOD1 (hSOD1) was randomly inserted into the 
genome of fertilized eggs from C57BL6XSJL F1 hybrid mice  (93). Modeling the 
neurodegenerative pattern of ALS, motor neuron atrophy and progressive paralysis 
occurred, ultimately resulting in death. With progression of the disease, the mice 
exhibited hind limb paralysis, deteriorating paw grip strength and endurance, muscle and 
tissue atrophy resulting in palpable bony structures, inability to groom or scavenge for 
food and water and limited mobility  (94, 95). Unique to the highly toxic SOD1 mutant in 
mice is that they also possess prominent ubiquitin-positive intracellular aggregates of 
SOD1 in their motor neurons and astrocytes (1). These aggregates can stop normal 
proteosomic function, causing a disruption in vital cellular functions and axonal transport 
systems (55) 
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Their disease pathology closely resembles that which is found in humans. 
Transgenic mice routinely develop paralysis in the hind limb within 3 and 12 months of 
age (69). Weakness in the hind limbs corresponds with increased progressive spinal 
motor neuron ascending and descending fibre track degeneration (69). Fragmented Golgi 
apparatus and neuroinflammation caused by astro- and microgliosis in damaged motor 
neurons also occur in these models  (17, 96-99). As well, mutations result in abnormal 
gait and movement  (95), altered axonal transport  (100, 101) and elevated levels of 
mSOD1, particularly in the brain and spinal cord  (99, 100, 102).  
Timeline of disease progression and death in mutant mice  
Age of onset, disease progression and duration can vary amongst the different 
models and can depend on genetic background  (103) and gene dosage (17). The life span 
and disease progression of ALS mouse models are inversely proportional to the amount 
of mutant genes inserted into the genome (gene dosage), which can affect the amount of 
mutant SOD1 protein present in the CNS (17). In high-copy mouse models, ~25 copies of 
the human transgene is randomly inserted into chromosome 12  (93). An indication of 
motor degeneration is observed via a change in gait of the high-copy G93A mice, which 
occurs between 85-110 d  (94, 95). Paralysis occurs at 124 ± 10 days and death occurs by 
~135 days  (94, 95). The main criticism that arises from using high copy mice is the fact 
that they have overexpression of the SOD1 protein up to 24-folds higher than what is 
found in humans which can result in phenotypic features that are not due to the SOD1G93A 
mutation itself  (104). However, extraneous effects on motor neurons have not been 
observed  (105). Conversely, low-copy mouse models (Tg(SOD1*G93Adl)1Gur 
(SOD1G93Adl or G1del) have also been developed by Jackson Laboratories via a deletion 
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in the transgene array of a SOD1G93A mouse (Jackson Laboratory Stock #002299). These 
low-copy mice carry ~eight to ten copies of the human SOD1G93A transgene  (105). 
Paralysis in these mice occurs between 24 and 34 weeks of age  (106). Death usually 
occurs at ~34 weeks  (105). Due to ethical reasons, endpoint must be established in order 
to prevent the animals from experiencing pain, distress and/or suffering  (107). Currently, 
there is no universal endpoint for rodent models of ALS accepted by all researchers  (95). 
There is an array of criteria that different labs utilize in order to establish endpoints. The 
most notable ones include a combination of two or more of the following criteria: 
righting reflex where mice are placed on their sides and must right themselves to sternum 
within 3-30 s otherwise they are euthanized, significant decrease in grip strength or motor 
performance, complete hindlimb paralysis and as a result inability to splay them, cannot 
obtain food or water, reduction in body weight from peak weight, eye infection, lack of 
self-grooming, lack of response to pain and/or a predetermined time where no 
spontaneous breathing or movement occurs  (95).  
  As of now, a righting reflex of at least 3 seconds is most commonly used to 
establish endpoint (95).  
Pathophysiology 
Oxidative Stress 
Oxidative stress occurs early in ALS and is present when damage in proteins, 
lipids and DNA generate reactive oxidative (ROS) and/or nitrogen (RNS) species. 
ROS/RNS are very reactive and present in the primary stages of neural dysfunction 
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where they interact with different components of the cell to initiate cell death and 
neurodegeneration.  
To generate ROS, activation of molecular oxygen must take place. 
Physiologically, univalent and divalent reduction of oxygen is an important attribute of 
aerobic cellular respiration and an intrinsic part of normal metabolism. Under normal 
conditions, ROS are used for cell functions such as alcohol oxidation or phagocytosis  
(108). Due to the toxicity of ROS, cells have developed powerful metabolic activities to 
deal with these harmful intermediates and to keep their concentrations in a harmless 
range. Problems arise when these regulatory systems that physiologically protect the cell 
break down and become destructive  (109).  
 Despite the mitochondria playing a central role in energy metabolism and cell 
survival, it can generate superoxide during energy production. In the mitochondrial 
electron transport chain, reducing equivalents in the form of NADH (insert in complex I) 
and FADH2 (insert in ubiquinone then goes to complex II) in the form of electrons flow 
through complex III and IV  (110). During this process, an electrochemical gradient (also 
known as membrane potential) is established as protons are pumped into the 
intermembrane space. High membrane potential or inhibition at the complexes can 
restrict electron flow and increases the chance of electron leakage from complex I and III. 
The electrons are then transferred to O2 for O2•- generation.  
Nitric oxide (NO) is a free radical in which the unpaired electron is delocalized 
between two different atoms  (111). In the CNS, it is produced as a major signaling 
molecule that can aid in regulating blood flow, neurotransmission, memory and synaptic 
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plasticity. NO can exert neuroprotective effects via two mechanisms: stimulation of 
sGC/cGMP system and induced expression of antioxidant and pro-survival pathways  
(78).  
Paradoxically, the same concentrations of NO that are purposeful for neurological 
function can also mediate cytotoxicity and neurodegeneration  (78). Under stressful 
conditions where superoxide is being generated, NO can trigger and amplify 
neurotoxicity. It can participate as a cytotoxic effector molecular and/or a pathogenic 
mediator when produced at high rates by either inflammatory stimuli-induced nitric oxide 
synthase (iNOS) or overstimulation of the constitutive forms (eNOS and nNOS)  (112). 
NO has the ability to form peroxynitrite (ONOO-), a dangerous and specific oxidant 
through a diffusion-limited reaction with superoxide  (113).  
Peroxynitrite, despite being a nonradical, is more damaging to human tissues than 
superoxide or nitric oxide. It is a strong oxidizing agent, oxidizing biological molecules 
including lipids, DNA and proteins. It is formed during the near instantaneous reaction of 
nitric oxide with superoxide anion  (114).  Low levels of peroxynitrite can be detoxified 
by enzymatic and nonenzymatic systems which allow the direct toxic effects of nitric 
oxide and superoxide to be neutralized  (115). The conversion of superoxide to 
peroxynitrite by NO is 3x faster than the rate at which normal SOD can catalyze 
superoxide to hydrogen peroxide  (116). Peroxynitrite levels are kept low because of the 
antioxidant capabilities of SOD, but small changes in NO and superoxide levels can 
greatly increase peroxynitrite formation  (114). Peroxynitrite cannot be directly measured 
because it is a transient molecule with a biological half-life of 10-20 ms 
(extramitochondrial peroxynitrite)  (117). Intramitochondrially produced peroxynitrite 
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has an even shorter half-life of 3-5 ms due to the large abundance of metalloproteins, 
fast-reacting thiols and CO2  (118). These half-lives are both shorter than that of nitric 
oxide (1-30 s)  (112).  
Glutamate Excitotoxicity 
Glutamate is part of the family of excitatory amino acids (EAAs) and is the most 
prominent excitatory neurotransmitter found in the central nervous system (CNS) with 
levels ranging from 5-10 mmol/kg tissue  (119). It is processed through several metabolic 
steps in the body. Initially, α-ketoglutarate is converted to glutamate (a nonessential 
amino acid) via deamination by the enzyme glutamate dehydrogenase or by 
transamination by transaminase enzymes which get metabolized through the Krebs 
(tricarboxylic acid) cycle in order to obtain succinate, fumarate and then malate, 
successively  (120). Cerebral glutamate is mainly produced in this manner. Another way 
that the body can obtain glutamate is by deamination of glutamine by the mitochondrial 
and possibly neuron-specific, phosphate activated enzyme, glutaminase  (121). 
A key characteristic of ALS is excessive stimulation of glutamate receptors which 
leads to excitotoxicity  (120). Glutamate is released by the presynaptic neuron into the 
synaptic cleft where it binds and activates ionotropic receptors (ligand-gated ion 
channels) and metabotropic receptors (G protein-coupled receptors). Both ionotropic and 
metabotropic receptors can each be divided into three classes and can be localized in 
presynaptic terminal, postsynaptic element and the surrounding astrocytes  (122, 123). 
Metabotropic receptors are divided into class I, II and III and serve as long-lasting 
modulators of glutamatergic transmission via G protein-regulated enzymes to produce 
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different second messengers such as cyclic adenosine monophosphate or Ca2+  (124). The 
ionotropic receptors are N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate (KA). These receptors are 
classified based on how responsive they are and their affinity to exogenous agonists  
(120). Contrary to the NMDA receptor, AMPA/KA receptors are impermeable to Ca2+. 
The NMDA receptors are known to be responsible for time-consuming and long lasting 
excitatory transmission and are permeable to Ca2+, Na+, and K+  (125). AMPA and KA 
have fast excitatory transmission led by the entrance of Na+ and K+ ions causing the 
depolarization of the neuron and the removal of the Mg2+ that blocks the NMDA 
receptors. The function of KA receptors is currently unknown. AMPA receptors lacking 
the subunit protein GluR2 (which makes them permeable to Ca2+), and NMDA receptors 
are the primary sources of intracellular Ca2+ in neurons due to their heightened 
permeability  (125). These receptors are expressed in motor neurons  (126, 127) and 
contribute greatly to glutamate excitotoxicity and the neurodegeneration that results from 
it.  
In a normally functioning synapse, the presynaptic terminal releases glutamate 
where it then binds and activates NMDA and AMPA receptors resulting in an influx of 
Na+ and Ca2+ /Na+ ions respectively, causing the post synaptic cell to become depolarized 
and ultimately lead to an action potential  (120). Under physiological conditions, 
intracellular calcium levels are maintained at a very low (micromolar) concentration 
relative to extracellular levels. Cytosolic free calcium concentration is regulated by 
plasma membrane calcium transporters such as the plasma membrane calcium pump 
(PMCA) and Na+/Ca2+ exchanger. Within the cell, the endoplasmic reticulum (ER) and 
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mitochondria are significant sources of calcium stores. Free calcium from the cytosol is 
moved to the mitochondria while calcium is sequestered by the ER.  
Once glutamate is no longer needed, its action is terminated when it is removed 
by systems mainly located in astrocytes that surround the synapse  (120). Astrocytes 
convert glutamate into the inactive glutamine, which is then moved to the presynaptic 
neuron via a glutamine-reuptake system and converted back to glutamate. Normal 
extracellular glutamate concentrations are in the low micromolar range which can span 
between 0.02-20 µM depending on the type of technology used to make the measurement  
(128, 129). These levels are too low to activate high-affinity glutamate receptors  (120). 
During an action potential, glutamate release exceeds 1 mM for <10 ms and then quickly 
returns to <20 nM once glutamate is taken up by astroglia and presynaptic neurons  (128).  
Compared to controls, plasma glutamate levels are elevated by ~70% in ALS 
patients  (130). Interestingly, glutamate levels are significantly decreased in all CNS 
regions studied in ALS patients (by 21-40%), with the greatest decrease observed in the 
spinal cord. However, there are mixed results as other studies have shown that glutamate 
levels are elevated in the CSF of sALS patients  (131). This was first observed by 
Rothstein et al., who found a decrease in maximal velocity of transport for high-affinity 
glutamate uptake in synaptosomes from the spinal cord (-59% P < 0.001), motor cortex (-
70%, P < 0.001) and somatosensory cortex (-39%, P < 0.05)  (132). The affinity of the 
transporter for glutamate was unchanged. 
Excitotoxicity occurs when the activation of glutamate receptors is excessive and 
dysregulated as a result of increased glutamate concentrations surrounding the vicinity of 
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the neuron. This is speculated to be an evolutionary adaptation as a means of protecting 
the integrity of the CNS with a cellular apoptotic back-up plan to eliminate diseased cells  
(125).  
This can also be induced by impaired glutamate uptake by astrocytes  (120). 
Excitatory amino acid transporters (EAATs) are a family of 5 proteins (EAAT 1-5) that 
use the Na+/K+ transmembrane gradient to transport glutamate back into the cells 
following its release  (133). EAAT1-2 is mainly located in astrocytes, whereas EAAT3-5 
is expressed mainly by cortical neurons. Astrocytes of SOD1 mice show an absence in 
glutamate transporter 1 (GLT-1) expression. EAAT2 (glutamate transporter 1 (GLT1) in 
rodents) is the predominant CNS glutamate transporter and accounts for over 90% of the 
total CNS glutamate uptake  (134, 135). This is consistent with findings of decreased 
GLT-1 expression around the time of spinal motor neuron degeneration in SOD1 mice  
(1, 136).  
The resulting excessive stimulation of the glutamate receptors causes a large 
influx of calcium ion into the post synaptic neuron by directly opening ions channels and 
affecting mechanisms necessary for calcium homeostasis. The influx of Ca2+and Na+ as a 
result of stimulated glutamate receptors causes membrane depolarization which can 
activate voltage-dependent calcium channels, further increasing intracellular Ca2+ levels. 
A decrease in the sodium gradient across the cell membrane disallows the Na+/Ca2+ 
exchanger to remove the excess intracellular calcium. Because ALS has also dysregulated 
ATP production, ATP-dependent calcium transporters and the energy-dependent 
Na+/Ca2+ exchanger are adversely affected further increasing intracellular calcium levels.  
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Heightened accumulation of glutamate-induced intracellular calcium leads to a 
destructive cascade of membrane, cytoplasmic and nuclear events which lead to 
neurotoxicity and degeneration  (137). This includes the activation of proteases, 
phospholipases, endonucleases and pro-oxidant enzymes  (138). Over-activation of many 
enzymes such as protein kinase C, calcium/calmodulin-dependent protein kinase II, 
phospholipases, proteases and NO synthase also occurs  (137). Some of these enzymes 
produce positive feedback loops which can increase the rate of neurodegeneration. For 
example, an increase in NO synthase activity can increase NO and superoxide levels, 
subsequently increasing peroxynitrite levels thus further inducing oxidative stress. 
Atrophy of neuronal cells can feed into a vicious cycle causing further elevation in 
extracellular glutamate levels and thus excitotoxic damage  (120).  
Inconsistent evidence in extracellular glutamate levels has been observed in 
chronic neurodegenerative diseases (139). Thus, the concept of “secondary” or “slow-
onset excitotoxicity” has been developed. The hypothesis states that despite normal 
extracellular levels, glutamate can cause the death of specific neurons that may have been 
hypersensitized by a genetic, endogenous or exogenous metabolic factor  (140). Potential 
factors that make the neuron susceptible to this condition include impairment of energy 
metabolism, trophic support, oxidative stress and altered GluR ionic permeability.    
Glutamate levels are significantly high in ALS patients. Assessment of plasma  
(141) and cerebrospinal fluid  (142) of 18-22 ALS patients showed their glutamate levels 
were double those in healthy controls and other neurological disorder patients. However, 
these results are inconsistent amongst other studies  (125).  
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Protein Nitration 
Peroxynitrite selectively nitrates protein tyrosine residues  (114), thereby 
damaging protein structure and function  (143). It does this via a multitude of 
mechanisms involving direct reactions with target molecules (e.g thiols, transition metal 
centers) or by secondary decomposition to yield nitrogen dioxide (NO2•), carbonate 
radical (CO3•-) and to a minor extent hydroxyl radicals (•OH), highly reactive free 
radicals. Protein nitration (addition of nitro group –NO2) is a very selective process that is 
limited to specific tyrosine residues on a small number of proteins. Under physiological 
conditions, both Cu/Zn SOD1 and zinc-deficient SOD1 can use peroxynitrite to catalyze 
tyrosine nitration  (143). Tyrosine nitration has been found in both sporadic and familial 
ALS patients as well as animal models via antibody identification and mass 
spectrophotometry  (89).  
Protein nitration results in the formation of 3-nitrotyrosine (3-NY). Free radicals 
(i.e. NO2• and CO3•-) oxidize tyrosine residues (one electron abstraction) to form tyrosyl 
radicals which combine with NO2• via diffusion-controlled termination reaction to form 
3-nitrotyrosine (3-NY). This peroxynitrite-mediated protein nitration has been observed 
in Tyr-108 of bovine SOD1 (113) and Tyr-34 of human SOD2  (144). 3-NY is an 
indicator of peroxynitrite-mediated damage that occurs in tissues and has been identified 
in the early stages of many neurodegenerative diseases in human and animal models  
(89).  
The mitochondria are particularly important organelles, since they are the main 
sites of ROS production in the cell. They are an important source and target of nitrating 
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species  (145). Although nitric oxide formation usually occurs outside the mitochondria, 
its ability to diffuse into the mitochondria and combine with superoxide to form 
peroxynitrite accounts for much of the disruption in mitochondrial metabolism and the 
nitration of mitochondrial proteins  (115). Peroxynitrite promotes mitochondrial oxidative 
damage by primarily causing oxidation, secondly nitration and to a lesser extent 
nitrosation of mitochondrial components  (145). It is noted that peroxynitrite can either 
diffuse from extramitochondrial compartments into the mitochondria (which can diffuse 
into the organelle) or be formed intramitochondrially  (118).  
Lipid Peroxidation 
Exogenous or endogenous peroxynitrite formation partially promotes 
mitochondrial lipid peroxidation due to its ability to produce free radicals  (118). 
Polyunsaturated fats, the main target, is essential to membrane fluidity and is the most 
susceptible to free radical attack and lipid peroxidation  (111). Free radicals such as •OH 
and NO2• attack double bonds of unsaturated fatty acids (including fatty acid side chains 
of membrane lipids), such as linoleic acid and arachidonic acid to abstract H• and 
generate very carbon-centered radicals which react with oxygen to produce peroxyl 
radicals. These go on to further attack other unsaturated fatty acid (specifically adjacent 
fatty-acid side chains)  (109). This chain reaction forms breakdown products which 
include 4-hydroxy-2,3-nonenal (4-HNE). Increased 4-HNE levels have been observed in 
the cerebrospinal fluid (CSF) of ALS patients  (146). 4-HNE induce toxicity by 
crosslinking to cysteine, lysine and histidine residues via a Michael addition. This leads 
to protein modification and dysfunction resulting in inhibition of the neuronal glucose 
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transporter type-3, the glutamate transporter GLT-1 and Na++K+-ATPases  (147). 4-HNE 
can also induce apoptosis at pathophysiologically relevant concentrations  (148).  
Antioxidant Enzymes 
Increase in oxidative stress is accompanied by an upregulation of antioxidant 
enzymes which work to detoxify oxidative molecules such as hydrogen peroxide in the 
cell  (149). As an oxidizing agent, hydrogen peroxide can impair cellular structures 
directly or react with iron or copper ions to generate •OH, a potent free radical. Aside 
from SOD1, there are other antioxidants the body utilizes in order to negate the effects of 
reactive oxidative species on neurons. Antioxidants such as SOD2, extracellular SOD3, 
glutathione peroxidase (GPx1) and catalase, have similar function as SOD1 and in some 
cases work with the enzyme to control superoxide and hydrogen peroxide levels. 
Glutathione peroxidase (GPx1) and catalase degrade hydrogen peroxide produced by 
SOD into water (GPx1 and catalase) and O2 (catalase)  (150). In 95-day-old ad libitum 
high copy G93A mice, the normal adaptive response is to upregulate SOD1 (7-10 fold), 
SOD2 (5-fold) and catalase (2-fold)  (83). Moreover, in similar animal models of ALS, 
90- and 105-day-old G86R mice exhibit an increase in the mRNA expression of GPx1, a 
response that is attributed to denervation  (151).   
SOD2 (or MnSOD), an endogenous protein and an isoform of the SOD family, is 
responsible for scavenging superoxide in the mitochondrial matrix. It also plays a critical 
role in inhibiting the intramitochondrial formation of peroxynitrite. SOD2 is necessary 
for survival, and most knockout mice die at birth as a result of severe neurological 
deficits and oxidative injury  (152). In transgenic mSOD1 mice, partial knockdown of 
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SOD2 accelerates motor neuron loss and disease progression  (153). The cofactor for 
SOD2 is manganese (Mn) which assists in catalyzing superoxide dismutation in the 
active site and has a tyrosine at position 34 at the entrance to the active site. SOD2 
converts O2•- into H2O2 and protects ROS-sensitive proteins in the ETC such as aconitase, 
α-ketoglutarate dehydrogenase and succinate dehydrogenase from oxidative damage  
(110). SOD2 is a specific target of nitration  (154). The agent responsible for SOD2 
nitration and subsequent inactivation in vivo is peroxynitrite, which rapidly reacts with 
the Mn in the centre of the enzyme  (155), nitrating and subsequently inactivating Tyr-34 
residue on the enzyme  (156). Tyr-34’s high susceptibility to peroxynitrite is probably 
due to the fact that the Mn atom can catalyze its site-specific nitration  (155) due to Mn’s 
close proximity to the active site. Inactivation of SOD2 results in impaired function and 
thus an inability to scavenge superoxide which results in oxidative damage in the 
mitochondria. SOD2 can also be damaged by ROS. NO can reversibly inhibit cytochrome 
c oxidase (complex IV) of the respiratory chain  (157) which inhibits electron flow, 
thereby increasing electron leakage at upstream complexes to form superoxide in the 
matrix and subsequently increase peroxynitrite production. When peroxynitrite nitrates 
and inactivate SOD2, it prevents the enzyme from scavenging superoxide and thus 
accelerates peroxynitrite formation  (78). Eventually, this can trigger apoptotic signaling 
of cell death, in part by thiol oxidation-dependent assembly of the permeability transition 
pore  (145).  
Catalase is a ubiquitous enzyme that degrades hydrogen peroxide to water and 
oxygen with high efficiency  (158). It is a porphyrin (ring structure) enzyme that contains 
iron. Catalysis of hydrogen peroxide by catalase occurs in two steps. The enzyme is 
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initially oxidized to a high-iron intermediate known as Compound I (Cpd I) which is 
subsequently reduced back to resting state by further reacting with hydrogen peroxide. 
Specifically, the oxidized iron binds to one of the oxygen atoms in hydrogen peroxide 
and splits it in order to attain water and oxygen (2H2O2 = 2H2O + O2) and to regain its 
reduced iron form  (158). Catalase is present in virtually all mammalian cell types  (108). 
Specifically, it is found in peroxisomes, highly dynamic cell organelles that play 
important roles in many metabolic pathways  (159). In order to function, peroxisomes 
interact with other cell organelles, including the mitochondria and the endoplasmic 
reticulum (ER) (159). In mammalian cells, peroxisomes and the mitochondria are 
metabolically linked  (160), cooperate in antiviral signaling  (161), and in defense share 
key components of their division machinery  (162). Disturbances in peroxisomal 
metabolism triggers signaling/communication events that ultimately result in increased 
mitochondrial stress  (163). For reasons unclear, increased ROS production inside 
peroxisomes rapidly disturbs the mitochondrial redox balance and leads to extreme 
amounts of mitochondrial fragmentation  (164). Thus, it is important for the cell to have 
well-functioning peroxisome and antioxidant activity. Astrocytes surrounding 
motoneurons possess high levels of antioxidant systems to protect neurons against 
oxidative stress  (165, 166).  Despite the glutathione redox system being the most 
pronounced antioxidant system in astrocytes, neuroprotection of striatal neurons in vitro 
against hydrogen peroxide is mainly due to catalase activity in astrocytes  (167). 
GPx1 is a hydrogen peroxide removing enzyme that requires selenium for proper 
function. It is found in the cytosol and mitochondrial matrix and removes H2O2 by using 
it to oxidize reduced glutathione (GSH) and converting it to oxidized glutathione 
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(GSSG). GSH is then regenerated from GSSG by glutathione reductase (GR), a 
flavoprotein enzyme that uses NADPH as a source of reducing power. GSH protects 
mitochondria against peroxynitrite-induced damage through different mechanisms  (168, 
169). GSH reacts with NO2•, CO3•- and •OH formed during peroxynitrite/CO2 reactions  
(144) and can reduce protein radicals (thiyl, tyrosyl, tryptofanyl) through one-electron 
oxidations. This yields glutathionyl radical (GS•), which is converted to GSSG. 
Glutathione is a tripeptide of glutamate, cysteine and glycine bound via a gamma peptide 
linkage. Glutathione synthesis is governed by the enzymes of the γ-glutamyl cycle where 
glutamate is added and removed at discrete steps  (170). γ-glutamyl cysteine ligase is the 
enzyme that utilizes glutamate to synthesize glutathione.  
  Postmortem studies on the precentral gyrus of 9 sALS patients showed that 
GPx1 activity (measured via spectrophotometric assay) was reduced significantly in 
sALS patients vs. controls ([mean ± SEM]: 13.8 ± 2.6 nmol/min/mg protein vs. 22.7 ± 
0.5 nmol/min/mg protein respectively)  (171). 
Neuroinflammation 
Inflammation is an important aspect of ALS pathology  (87, 172). The 
cerebrospinal fluid (CSF) of ALS patients has shown abnormalities in the pro- and anti- 
inflammatory cytokines and growth factors which include IL-10, IL-6, GM-CSF, VEGF 
and IFN-γ  (173).  
Sources of pro- and anti- inflammatory cytokines within the CNS are astrocytes 
that protect and promote survival of motor neuron cells. They are the most prevalent cell 
type found in the CNS. As well as their important structural role, they also regulate 
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homeostasis of the external environment, influence neuronal excitability by modulating 
the release of neurotransmitters and ions and promote neuron health by releasing growth 
factors  (174, 175).  
In comparison to ALS patients, astrocytosis and neuroinflammation is more 
dramatic in rats and mice possessing the SOD1 mutation  (78, 84). This can possibly 
explain why degeneration occurs at a much faster rate in animals vs. humans. Upon 
activation by lipopolysaccharides (LPS) or cytokines, astrocytes adopt a toxic profile via 
mechanisms involving inflammatory-inducible NOS (iNOS) expression  (176). Brief 
exposure to peroxynitrite, but not hydrogen peroxide, is sufficient to induce an 
inflammatory response in isolated spinal cord astrocytes which would initiate apoptosis 
of subsequently co-cultured motor neurons  (177). Inflammation in mSOD1 is associated 
with apoptosis via activation of caspase 1 and caspase 3  (178).  
Neurotrophic factors 
Survival of motor neurons relies heavily on appropriate support of neurotrophic 
factors  (179, 180). Brain derived neurotrophic factor (BDNF), glial cell derived 
neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF) can rescue 
motor neurons from different insults to the cell  (87). In disease, activated astrocytes 
affect motor neurons by reducing their release of neurotrophic factors. Evidence from cell 
cultures show that both exogenous and endogenous mSOD1 can increase the production 
of pro-inflammatory cytokines such as IL-6 and TNF-α and free radicals  (181). The 
presence of mSOD1 can also reduce the expression of BDNF and IGF-1 which can 
amplify the effects of pro-inflammatory cytokines on vulnerable motor neurons  (87).   
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Motor neurons cultured from embryonic rat spinal cord tissue exposed to BDNF 
constitutively express endothelial NOS (eNOS), which supports motor neuron survival by 
stimulating cyclic GMP (cGMP) synthesis through NO binding to the heme group of 
soluble guanylate cyclase  (182).  
Removal of neurotrophic factors increases NO production by upregulating 
neuronal NOS (nNOS) in cultured motor neurons. Deprivation of trophic factors also 
stimulates co-generation of superoxide, which promotes the endogenous production of 
peroxynitrite  (78).  
Apoptosis 
Endogenous production of peroxynitrite by cultured motor neurons can activate 
apoptotic cascades  (183). In the presence of several different neurotrophic factors, motor 
neurons isolated from spinal cords or embryonic rats develop the phenotype of a mature 
motor neuron over a period of ~1 week  (183). If at any point the trophic factors are 
withdrawn, ~50% of the motor neurons undergo apoptosis  (184). As well, neurotrophic 
factor deprivation leads to increased 3-NY immunoreactivity and activates apoptosis 
within 24 h in more than 60% of cultured neurons  (183). NO-dependent activation of 
cGMP can prevent apoptosis in motor neurons by blocking the expression of nNOS 
through sequestration of free intracellular calcium via cGMP and inhibition of calcium 
influx through NMDA receptor  (185). Motor neuron death requires the simultaneous 
production of both nitric oxide and superoxide, suggesting that peroxynitrite serves as an 
early intermediate for activating apoptosis after trophic-factor deprivation  (183).  
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Excessive ROS generation leads to dysregulation of intracellular calcium 
signaling. Calcium is an important mineral for signal transduction, and because of this 
calcium is sensitive to different stimuli and can elicit a multitude of responses in the cell. 
Evidence suggests that a disruption in calcium homeostasis is an important property of 
neurodegenerative diseases as it leads to the breakdown of a large amount of cellular 
processes. Abnormal influxes of calcium levels stimulate multiple pathways that lead to 
the activation of apoptotic cascades  (109). ROS-induced calcium influxes lead to 
excitotoxic responses such as activation of the glutamate receptor that trigger a cascade 
(i.e. caspase 3 cascade) of events that lead to cell death. During apoptosis, cytochrome c 
is released by the mitochondria to the cytosol possibly via channels that make up the pro-
apoptotic Bax  (186). Bcl-2 block the release of cytochrome c, possibly by interfering 
with membrane insertion and pore formation by the Bax protein or through disruption of 
the mitochondria’s membrane potential and membrane homeostasis  (186). High 
expression of bcl-2 protein in SOD1G93A mice is able to slow disease onset and increase 
survival by 3 to 4 weeks  (187) 
A major outcome of SOD1 mediated cell death is the activation of caspase-3, an 
important cysteine-aspartate protease that is responsible for degrading cell components 
important for apoptosis (1). In SOD1G93A models, release of cytochrome c from the 
mitochondria is followed by activation of caspase-9, which subsequently activates 
caspase-3 by cleaving it. Caspase-3 goes on to cleave specific cell protein and DNA, 
which ultimately leads to cell death.   
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Vitamin D 
Vitamin D is a fat-soluble vitamin which functions like a steroid hormone to 
regulate immune function. It is important for different biological processes in the human 
body and is essential for health, growth and development  (188). It has great importance 
for the metabolism of phosphorous and calcium and has anti-inflammatory, anti-
proliferative and modulatory effects on CNS components such as neurotrophins, growth 
factors and neurotransmitters  (189). On a cellular level, vitamin D regulates more than 
200 genes and aids in cell angiogenesis, apoptosis and differentiation  (190). 90-100% of 
human vitamin D intake is acquired from the contact of the sun’s ultraviolet B (UVB) 
rays on skin  (188, 191). 7-dehydrocholesterol, which lies under the skin, becomes 
converted into a pre-form of vitamin D once it is in contact with UVB rays at 
wavelengths of 290-315 nm. As a result of the body’s temperature, the pre-form is then 
converted into cholecalciferol, better known as vitamin D3, after which it goes into the 
blood stream and enters the circulation. Cholecalciferol can also be acquired from the diet 
(10% of vitamin D intake) via animal products  (191). Another form of the vitamin, 
ergocalciferol or vitamin D2, is acquired from plant products  (191). Though a definitive 
difference has not been found between the body’s efficiency towards the absorption of 
ergocalciferol vs. cholecalciferol, many studies have found that vitamin D2 is less 
effective in humans compared to D3  (192). Once the vitamin enters circulation, it is 
transported to the liver where it is hydroxylated to become calcidiol or 25-
hydroxyvitamin D (25(OH)D3) via the enzyme 25-hydroxylase (CYP2R1 and 
CYP27A1). 25(OH)D3 is the most predominant metabolite in circulation and is utilized 
as a means of evaluating overall vitamin D status in individuals  (191). Calcidiol’s use in 
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research as an indicator is also due to its long half life of 20-90 days, in comparison to 
calcitriol which has a half life of only 12-16 hours  (193). In order to activate the vitamin, 
calcidiol must undergo hydroxylation in the kidneys via 25(OH)D3 1-α-hydroxylase 
(CYP27B1) to synthesize calcitriol or 1α, 25-dihydroxyvitamin D3 (1α, 25(OH)2D3)  
(188, 191).  Though 1-α-hydroxylase is found mainly in the kidneys, extrarenal 1-α-
hydroxylase is expressed in many vitamin D target cells such as skin, lymph nodes, 
colon, pancreas, adrenal medulla, brain and placenta  (194). For calcitriol to exert its 
effects, it can directly interact with the cell membrane or can act as a gene transcription 
modulator by binding to vitamin D receptors (VDR) either at a nuclear level or embedded 
within the cell membrane  (191). Many cells within the body contain VDR allowing 
vitamin D to exert its effect on them. Such interactions can also allow calcitriol to exert 
its immunomodulatory effects  (195). 1-α-hydroxylase is essential in allowing high-
affinity binding to VDR. Though both can bind to the receptor, calcidiol affinity to VDR 
is 100-200 times lower than calcitriol  (196) 
According to Health Canada, children and adults aged 9-70 years have a 
recommended dietary intake (RDA) of 600 IU (15 mcg) of vitamin D per day  (197). 
Food sources high in vitamin D content are fish such as salmon, cod and halibut, cheese 
and other dairy, or foods fortified with the vitamin such as orange juice and cereals  
(188). Both vitamin D2 and D3 can also be supplemented in 400, 800, 1000 and 2000 IU 
per one dose  (188). Vitamin levels as high as 10 000-15 000 IU can be obtained via 10-
15 minutes of sun exposure  (188). There are multiple influencing factors that can affect 
the amount of vitamin D production, including time of day, season, skin colour, clothing, 
use of sunscreen and latitude. For adequate vitamin D levels, it is recommended to 
 35 
expose large body parts such as arms and legs to sunlight for 5-30 minutes, twice a week  
(188). The most advantageous serum levels are between 90-100 nmol/L which is 
necessary in order to optimize the metabolism of calcium and phosphorous (to prevent 
osteoporosis and pathological fractures), and aid in preventing autoimmune diseases such 
as MS, infections, and three major cancers (colon, breast and prostate)  (189). 
Calcidiol and Calcitriol Serum Levels 
Currently, there is much controversy surrounding adequate 25(OH)D3 serum 
levels for good health. The variable normal ranges in different populations can be 
possibly a result of adaptation  (198). The Institute of Medicine recommends 50 nmol/L  
(197). However, different studies have suggested different cut-off points for serum levels. 
Holick et al suggest <50 nmol/L to be deficient, 52.5-72.5 nmol/L to be sufficient and 
>72.5 nmol/L to be optimal  (199). Hanley et al suggest <25 nmol/L to be deficient, 25-
75 nmol/L to be sufficient and >75 nmol/L to be optimal  (200). In adolescents 12-19 y, 
Saint-Onge et al suggest <27.5 nmol/L to be deficient, 27.5-50 nmol/L to be sufficient 
and >50 nmol/L to be optimal  (201). Other studies have suggested minimum serum 
levels of 75 nmol/L  (202), upper limit of 250 nmol/L  (189) and toxic levels at 750 
nmol/L  (189). Serum calcidiol concentration of 75 nmol/L is considered to be optimal, 
since lower levels cause a stimulation of parathyroid hormone (PTH), and the occurrence 
of osteoporosis and pathological fractures increases  (189). Conversely, the normal serum 
concentration of 1α, 25(OH)2D3  is clearly defined as being 0.03-0.14 nmol/L  (203).  
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Vitamin D toxicity 
Vitamin D toxicity (hypervitaminosis D) results from excessive vitamin D intake. This 
results in an elevation of plasma concentrations of vitamin D3; 25(OH)D3; 24,25(OH)2D3; 
25,26(OH)2D3; and 25(OH)D3-26,23-lactone, although toxicity rarely leads to a rise in 
plasma 1α,25(OH)2D3  (204). 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) plays an 
important role in vivo, regulating concentrations of both the precursor 25(OH)D3 and the 
hormone 1α,25-dihydroxyvitamin D3. CYP24A1 degrades both 25(OH)D3 and 
1α,25(OH)2D3 through a side-chain hydroxylation and cleavage pathway known as C-24 
oxidation. Studies in the CYP24A1-null mouse has shown that CYP24A1 absence leads 
to an inability to degrade vitamin D metabolites resulting in hypercalcemia (high 
intracellular calcium levels), nephrocalcinosis, and death in 50% of animals  (205). A 
study by Shephard and DeLuca investigated hypervitaminosis D in acutely intoxicated 
rats fed graded oral doses of vitamin D3 (0.65 to 6500 ng/d for 14 d) or calcidiol (0.46 to 
4600 ng/d for 14 d)  (206) Plasma vitamin D3 and calcidiol concentrations rose to 
micromolar levels in rats with the highest intakes of vitamin D3, resulting in marked 
hypercalcemia. The study showed that toxicity is not reached with calcidiol 
concentrations of 100-250 nmol/L, and that it is only when concentrations exceed 375 
nmol/L that hypercalcemia occurs.  
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ALS and Vitamin D 
Vitamin D and ALS pathophysiology 
Vitamin D deficiency has been associated with the development of inflammatory and 
immune diseases such as type II diabetes  (207), multiple sclerosis  (195), dementia and 
Alzheimer’s disease (208).  
In rat mesencephalic culture, pretreatment with calcitriol protected dopaminergic 
neurons against the neurotoxic effects of glutamate and dopaminergic toxins  (209). As 
well, 24-hour pretreatment with calcitriol inhibited the increase in intracellular ROS, after 
exposure to H2O2.  In the rat model of perinatal asphyxia, calcitriol was neuroprotective 
when it was co-applied with glutamate or even after a delay of up to 6 hours during a 24-
hour excitotoxic exposure to hippocampal and neocortical cells. As well, calcitriol 
reduces glutamate-induced caspase-3 activity in cerebellar granule cells dependent on cell 
maturity  (210).   
When investigating the effects of vitamin D on biomarkers of oxidative stress in 
obese children aged 7-14 y, obese children with calcidiol insufficiency (<50 nmol/L) had 
significantly elevated IL-6, malondialdehyde (MDA; a marker of lipid peroxidation) and 
3-NY levels vs. non-deficient obese children (>50 nmol/L)  (211). A partial correlation 
analysis showed an inverse relationship between calcidiol and 3-NY (r = -0.424, P = 
0.001). 
It has been shown that SOD is induced by activated vitamin D  (212). In rats, 
supplementation with calcitriol can increase SOD activity levels and prevent DNA 
damage  (213). In the arterial walls of rabbits, injection with high doses of calcitriol (10 
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000 IU/kg) was able to increase antioxidant activity (SOD, GPx and catalase) and lower 
lipid peroxidation  (214).    
Vitamin D increases neurotrophic factors which may assist in prolonging the 
lifespan of ALS patients. Insulin-like growth factor (IGF-1) and glial cell line-derived 
neurotrophic factor (GDNF) are examples of neurotrophic factors that are essential for 
the survival of motor neurons in vivo and in vitro  (180). Vitamin D can induce the action 
of IGF-1 by increasing the number of IGF-1 receptors  (215). GDNF has neurotrophic 
effects on several different types of neurons in vivo, including dopaminergic neurons of 
the substantia nigra  (216, 217) and noradrenergic neurons of the locus coeruleus  (218). 
Vitamin D3 has the ability to enhance GDNF mRNA expression in vitro and in vivo  
(219) 
Experimental evidence suggests that the metabolism of vitamin D in the CNS is 
responsive to inflammation  (220). Experiments conducted in female experimental 
autoimmune encephalomyelitis (EAE) mice, a model of multiple sclerosis (MS), have 
shown that consumption of vitamin D3 reduced the inflammation before EAE 
development  (221). A study assessing circulating inflammatory cytokines in young 
adults (25-42 y) as well as serum calcidiol found that serum levels of subjects in the 
insufficient group (calcidiol ≤80 nmol/L, n = 14) had significantly higher pro-
inflammatory cytokines (IL-1β, IL-2,  interferon-γ, TNF-α) (P <  0.05) vs vitamin D-
sufficient adults  (222). The study suggested that vitamin D insufficiency, in part, could 
result in pro-inflammatory stress. Vitamin D also has positive effects on anti-
inflammatory cytokines such as interleukin 10 (IL-10). In a study of 93 patients with 
congestive heart failure (CHF) where vitamin D3 was supplemented at 2000 IU/d for 9 
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mo (which increased serum calcidiol levels from 35 nmol/L to approximately 67 
nmol/L), IL-10 levels were 43% higher than baseline (2 pmol/L vs. 1.4 pmol/L, 
respectively)  (223). The study suggested that vitamin D3 reduces the inflammatory 
milieu in CHF patients and has the potential to serve as an anti-inflammatory agent for 
future disease treatment.  
Clinical trials of vitamin D supplementation in ALS patients 
In a retroactive study by Karam et al, of 37 consecutive ALS patients with an 
initial mean serum calcidiol of 55 nmol/L (81% had calcidiol < 75 nmol/L, and 43% had 
calcidiol < 50 nmol/L)  (224) 20 of these patients with calcidiol < 75 nmol/L were 
supplemented with 2000 IU of vitamin D3 for 12 months. ALS severity was recorded 
(ALSFRS-R) at the beginning and in 3-month increments afterwards. At the 6-month 
follow-up, median serum calcidiol rose in the supplemented group from 45 nmol/L to 
77.5 nmol/L, and ALSFRS-R scores of all patients declined. However, at the 9-month 
follow up these scores had declined significantly less in the vitamin D group (P = 0.02). 
Supplementation with vitamin D showed trends towards higher ALSFRS-R scores at 3 
and 6 months after age and baseline vitamin D levels were adjusted (P = 0.07 and P = 
0.09 respectively). These results are supported by a retrospective study that found that 
ALS patients with serum calcidiol levels <25 nmol/L increased their death rate by 6 fold, 
their rate of decline by 4 times and were associated with a marked shorter life expectancy 
compared to patients with calcidiol levels >75 nmol/L  (225).  
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Effects of vitamin D in the G93A mouse model of ALS 
 Vitamin D-deficient G93A mice had lower paw grip endurance and motor 
performance and higher clinical score when compared to AI vitamin D3 mice  (226). 
Alternatively, G93A mice supplemented with 10x AI had greater paw grip endurance and 
motor performance score compared to AI mice  (227). In addition, 50x AI G93A mice 
had a greater paw grip endurance during disease progression compared to AI mice  (228).  
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RATIONALE, OBJECTIVES, HYPOTHESES AND PILOT STUDIES 
 
Rationale 
Given that vitamin D modulates several pathophysiologies common to ALS, it 
can serve as a potential therapeutic. 
Objectives 
To investigate the effects of dietary vitamin D3 restriction, adequacy and 
supplementation on markers of oxidative damage, antioxidant enzymes, inflammation, 
apoptosis, neurotrophic factors and neuron count in the spinal cord of the G93A mouse 
model of ALS. 
Hypotheses 
Based on our planned comparisons, we expect the following results: 
1. For 4-HNE and 3-NY: 
a. 50x vitamin D (HiD) lower vs. adequate intake (AI) in males but not 
females. 
b. D3 Deficiency (DEF) higher vs. AI in both males and females. 
2. Antioxidant enzymes SOD2, catalase and GPx-1: 
a. HiD higher vs. AI in males but not SOD2 and catalase in females  
b. DEF lower vs. AI in both males but not GPx1 in females 
3. For TNF-α and IL-6: 
a. HiD lower vs. AI in males but not females 
b. DEF higher vs. AI in males and females 
TNF- α and IL-6 are released by both neurons and microglia during spinal cord damage 
to initiate a pronounced inflammatory response in the spinal cord  (87) 
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4. Because IL-10 is an anti-inflammatory cytokine, we expect: 
a. HiD higher vs. AI in males but not females.  
b. DEF lower vs. AI in both males and females.  
Because of the effects of toxicity in female HiD mice, damage and thus inflammation 
will be higher in the animal, inhibiting the release of the pro-inflammatory IL-10. 
5. Ratio of Bax/Bcl-2 and cleaved/pro-caspase (CASP3):  
a. HiD lower vs. AI in males but not females 
b. DEF higher vs. AI in males and females 
Based on studies by Parkhomenko et al  (229), higher CASP3 was observed in HiD 
female gastrocnemius mice which was likely due to toxicity. These results are predicted 
to also be observed in the spinal cord because of previous studies by Gianforcaro et al 
who found a 31% greater disease severity prior to disease onset and reduced food intake 
(absolute and corrected for body weight) in HiD females  (228) 
6. GDNF: 
a. HiD higher vs. AI 
b. DEF lower vs. AI 
7. ChAT and SMI-36/SMI-32 ratio: 
a. HiD higher vs. AI in males but not females 
b. DEF lower vs. AI in males and females 
As a result of a predicted increase in apoptosis in HiD females and DEF mice, neuronal 
count is predicted to be lower in these groups.  
 43 
Pilot Studies 
In 2013, we published a paper investigating the influence of vitamin D 
supplementation and deficiency on disease severity and progression as well as functional 
outcomes (226, 228) but not molecular outcome measures. In addition, no other study has 
investigated the impact of vitamin D on the spinal cords of ALS mice. Hence, this study 
was established as a pilot, because -1- females showed differing results than males when 
supplemented with 50x AI, -2- vitamin D’s effect is tissue-specific (changes in one tissue 
may not be reflected through changes in other tissues. Indeed, the results in the CNS in 
these studies did not translate exactly to the changes observed in muscle cells. This is due 
to the fact that calcidiol is not converted to calcitriol in the muscle, whereas it is in the 
spinal cord), and -3- the evidence that there is sexual dimorphism in ALS, independent of 
the toxic effects of 50x AI vitamin D. Given the above, it is evident that the interaction 
between vitamin D and the mouse model of ALS presents with a complex disease that is 
difficult to elucidate without a pilot study. Also, since there are several molecular 
pathways contributing to the pathophysiology of ALS, and since vitamin D influences 
several cellular processes throughout the body, it was not possible to run a large study 
and analyze dozens of outcome measures to elucidate the many pathways common to 
both ALS and vitamin D function without first conducting a pilot study. Based on the 
findings in these pilot studies, we have paved the way for us and other researchers to be 
more specific with sample analysis in future studies. In addition, no other study has 
investigated the impact of vitamin D on the spinal cords of ALS mice. Hence for all these 
reasons, and notwithstanding our 2013 publication, these are pilot studies. 
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Statistically, P values are set by investigators in an arbitrary fashion (please consult with 
a statistician about this matter). There is no excellent reason why some disciplines use P 
values of 0.05, whereas others use P values of 0.10 or even 0.15. The reasons are all 
excellent, and no reason is better than the other. It is customary in the life sciences 
discipline to use a P value of 0.10 for pilot studies to avoid type II error. The results of 
our current studies are not artifactual, and the choice of a P value of 0.10 for these pilot 
studies does not lead to inaccurate conclusions. 
Ethically, pilot studies are important to move scientific discovery forward. In vivo studies 
are costly and involve stringent ethical standards. To include a high number of animals 
that may yield insignificant results without a priori understanding which molecular 
pathways are involved is not only unethical but also irresponsible. Our pilot studies 
contribute to science vis-à-vis vitamin D’s role in ALS specifically, and 
neurodegenerative diseases in general. As well, our studies are proof-of-concept that 
present molecular biologists, nutrition physiologists and clinicians with a new potential 
therapeutic as well as the specific pathways that they would need to investigate when 
conducting in vitro, animal and human studies. This is a major discovery for a fatal 
disease that hitherto has no cure or even an effective drug (Riluzole has been mediocre at 
best, and has proven to be inefficacious, and very costly). So far, vitamin D has proven to 
be a promising, accessible, inexpensive, potential therapeutic for ALS, and probably 
other neurodegenerative diseases. 
The purpose of our studies was to investigate the effect of vitamin D on the spinal cord of 
G93A mice and stimulate further scientific exploration, with future studies consisting of 
higher number of subjects. Pilot studies usually entail smaller sample sizes. However, a 
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smaller sample size results in higher variability, causing an increase in P values. With the 
use of P = 0.10, we were able to draw attention to all notable differences in outcome 
measures. Statistically, any P value is arbitrary and does not affect the final conclusions 
drawn for the obtained results. The results of our current studies are not artifactual and 
our choice of P = 0.10 did not lead to inaccurate conclusions. Actually, choosing a P 
value of 0.05 in a pilot study would result in type II error, and hence to inaccurate 
conclusions.  
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Abstract 
Background: Vitamin D3 (D3) at 50x the adequate intake (AI) improves paw grip 
endurance in G93A mice. However, apoptosis increases in female quadriceps, indicating 
a threshold of toxicity. ALS is a neuromuscular disease characterized by progressive 
degeneration of upper and lower motor neurons. Objective: We analyzed the spinal cords 
of G93A mice following dietary D3 supplementation at 50x the AI for oxidative damage 
(4-HNE, 3-NY), antioxidant enzymes (SOD2, catalase, GPx1), inflammation (TNF-α, IL-
6, IL-10), apoptosis (Bax/Bcl-2 ratio, cleaved/pro-caspase 3 ratio), neurotrophic factor 
(GDNF), and neuron damage (ChAT, SMI-36/SMI-32 ratio). Methods: Beginning at age 
25 d, 41 G93A mice were provided food ad libitum with either adequate (AI; 1 IU D3/g 
feed; 12 M, 11 F) or high (HiD; 50 IU D3/g feed; 10 M, 8 F) D3. At age 113 d, the spinal 
cords were analyzed for protein content. Because this was a pilot study, differences were 
considered significant at P ≤ 0.10. Results: HiD females had 14% higher 3-NY (P = 
0.065), 21% lower catalase (P < 0.001), 18% higher GPx1 (P = 0.101), 21% higher TNF- 
α (P = 0.003), 13% lower IL-10 (P = 0.042), 13% higher cleaved/pro-caspase 3 ratio (P = 
0.010) and 18% lower ChAT (P = 0.024) vs. AI. HiD males had 16% lower 3-NY (P = 
0.073), 24% lower IL-6 (P = 0.085), 26% lower cleaved/pro-caspase 3 ratio (P = 0.009) 
and 19% lower SMI-36/SMI-32 (P = 0.098) vs. AI. Conclusion: In G93A mice, dietary 
D3 at 50x AI is toxic in the spinal cord of females but attenuates disease pathophysiology 
in males. This is in accord with results in the quadriceps, as well as functional and 
disease severity outcomes. Future studies need to identify the sex-specific therapeutic 
dose of D3 for ALS.   
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Introduction 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease is the 
most commonly occurring adult-onset motor neuron disease of unknown cause  (1, 2) and 
is typically diagnosed between 45 and 60 years of age  (3, 4). It is characterized by 
degeneration of upper and lower motor neurons, resulting in skeletal muscle atrophy  (5) 
and death by respiratory failure within 3-5 years of initial symptoms  (6-8).  90% of cases 
are of unknown etiology (sporadic ALS; sALS)  (3, 9), whereas the other 10% have 
inherited genetic mutations  (3, 10) (familial ALS; fALS), ~12% of these cases being a 
result of a mutation in the Cu2+/Zn2+ super-oxide dismutase 1 (SOD1) gene  (11-14). The 
most commonly used animal model of ALS is the G93A mouse model  (15) that 
transgenically overexpresses the mutant SOD1 gene  (10).  Their disease pathology and 
neurodegenerative patterns closely resemble that which is found in ALS patients  (10). 
On a cellular level, excessive stimulation of glutamate receptors  (16) leads to a large 
influx of calcium ion into the post synaptic neuron, resulting in a destructive cascade of 
membrane, cytoplasmic and nuclear events  (17). These include oxidative damage  (18, 
19), oxidative stress  (20, 21), inflammation  (22), compromised neurotrophic factor 
release  (22) and apoptosis  (13).  
The only available therapy for ALS is the antiglutamatergic drug, riluzole, even 
though nutrition-based interventions have shown differing levels of improvements in 
animal models of ALS  (23). Daily 100 mg oral consumption of the drug may extend life 
for approximately 2-3 months and may increase the likelihood of survival in the first year 
by 9%  (24). However, riluzole is very expensive, costing approximately $10,000/year in 
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the US and £4056/year in the UK  (25) Thus, alternative therapies need to be 
investigated.  
Vitamin D is a fat-soluble vitamin with hormone-like properties that is essential 
for health, growth and development  (26). Vitamin D3 and/or its metabolites [calcidiol 
(25(OH)D3) and calcitriol (1,25(OH)2D3)] can protect dopaminergic neurons against the 
neurotoxic effects of glutamate and dopaminergic toxins (27), and has anti-inflammatory 
and modulatory effects on CNS components such as neurotrophins and growth factors  
(28). Vitamin D treatment can improve compromised functional outcomes and muscle 
physiology in humans and rodents, whereas vitamin D receptor (VDR) knockout mice 
have loss of motor function and muscle mass (29). Vitamin D reduces the expression of 
biomarkers associated with oxidative stress and inflammation in diseases that share 
common pathophysiologies with ALS.  
In response to oxidative stress and inflammation, vitamin D also increases 
antioxidant capacity in a multitude of associated disease pathologies.  In human prostate 
cancer cell cultures, the SOD gene is highly induced by calcitriol  (30, 31). In 
phenobarbital induced rat hepatocarcinogenesis, supplementation with calcitriol increases 
SOD activity levels and prevents DNA damage  (32). In the arterial walls of rabbits, 
injection with high doses of calcitriol (10 000 IU/kg) increased antioxidant activity 
(SOD, GPx and catalase) and decreased lipid peroxidation  (33).  Administration of 5000 
IU/kg bwt/d calcitriol to diabetic rats enhanced SOD, catalase and GPx (207, 52 and 
72%, respectively) in the liver and kidneys compared to diabetic controls  (34).  
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In a retrospective study by Karam et al in ALS patients, supplementation with 
2000 IU of vitamin D3/day for 9 months improved ALS functional rating scale score 
(ALSFRS-R)  (35). We have previously shown the benefits of 10x and 50x the adequate 
intake (AI) of vitamin D3 (D3) supplementation in G93A mice  (36-40). Functionally, D3 
supplementation improved motor performance  (37) and paw grip endurance (PaGE)  (36, 
37), and in their quadriceps D3 supplementation increased antioxidant capacity  (40) vs. 
AI. However, the underlying mechanisms in the spinal cord for the above observations 
have not been delineated. 
Based on our previous studies in the G93A mouse model of ALS (28-30, 32) and 
those in ALS patients  (35), the objective of this study was to examine the effects of high 
levels of vitamin D3 supplementation (50 IU/g feed) vs. adequate intake (1 IU/g feed) on 
spinal cord biomarkers of oxidative damage, antioxidant enzymes, inflammation, 
apoptosis, neurotrophic factors and neuron damage in the G93A transgenic mouse model 
of ALS.  
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Methods 
Ethical Statement 
The experimental protocol that was used in this study followed the guidelines of 
the Canadian Council of Animal Care and was approved by York University Animal 
Research Ethics Board (protocol # 2007-9).  All the necessary steps were taken to 
minimize suffering and distress to the mice in the study.  
Animals 
Male B6SJL-TgN(SOD1-G93A)1Gur hemizygous mice (No. 002726) were 
harem-bred with non-affected female B6SJL control mice (No. 100012; Jackson 
Laboratory, Bar Harbor, ME). We identified the presence of the human-derived G93A 
transgene by using polymerase chain reaction (PCR) amplification of DNA extracted 
from ear tissue as outlined by Sigma-Aldrich (XNAT REDExtract-N-Amp Tissue PCR 
Kit; XNAT-1KT). All breeding mice were housed 3 females per 1 male, and consumed 
Research Diet AIN-93G (1 IU D3/g feed; Research Diet, New Brunswick, NJ). All 
animals were housed individually at age 25 d in a 12 h light/dark cycle.  
Study Design 
41 (22 M, 19 F) G93A mice consumed a diet that contained an adequate intake of 
vitamin D3 (1 IU/g feed; Research Diet AIN-93G; Product # D10012G; Research Diets 
Inc, New Brunswick NJ [38]) ad libitum after weaning (21 d). At age 25 d, the mice were 
individually caged and divided into one of two groups: 1) adequate vitamin D3 (AI; 1 IU 
D3/g feed; 12 M, 11 F; Research Diet AIN-93G) or 2) high vitamin D3 (HiD; 50 IU D3/g 
feed; 10 M, 8 F; product # D10030802; Research Diets Inc, New Brunswick, NJ) (Table 
1).  
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When the mice reached a clinical score (CS; disease severity) of 3.0, food and 
calorie-free gel (Harlan-Gel, Harlan Teklad, Madison WI) were placed on the floor of the 
cage to fulfill ethics requirements. Endpoint was determined as previously described by 
Solomon et al 2011  (41). The calorie-free gel contained synthetic polymers (WATER 
LOCK® superabsorbent polymer G-400, G-430, G-500, G-530; 95% by weight) and 
methanol (4.5% by weight). A summary of food intake, vitamin D3 intake and body 
weight of the G93A mice can be found in Table 1.2. Two researchers who were blinded 
to the diets conducted all measurements.  
Table 1.1  Nutrient content of the adequate intake (AI) and high (HiD) vitamin D3 diets 
Nutrient Diet 
 AI HiD 
Energy (kcal/g) 4 4 
Carbohydrate (%) 64 64 
Protein (%) 20 20 
Fat (%) 7 7 
Vitamin D3 (IU/g) 1a 50a,b 
Calcium (%) 0.5c 0.5c 
Vitamin mix V10037 (mg/g) 10 10 
Mineral mix S100022G (mg/g) 35 35 
 
Diets provided by Research Diets (based on AIN-93G; New Brunswick, NJ; AI 
product # D10012G; HiD product # D08080101;). 
a, included in vitamin mix V10037  
b, additional vitamin D3 was added to reach 50 IU/g feed.  
c, included in mineral mix S100022G (42) 
*  table adopted from Gianforcaro et al, PLoS ONE 2013 (36)  
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Table 1.2 Food intake, vitamin D3 intake and body weight of G93A mice.   
Measurements Males Females 
 AI (n=12) HiD (n=10) AI (n=11) HiD (n=8) 
Food intake (g/d)* 3.5±0.1 3.4±0.1 3.4±0.1 3.1±0.1 
Food intake (mg/g b.wt./d)* 151.5±5.4 155.2±4.8 195.0±6.7 171.5±5.4 
Vitamin D3 intake (IU D3/d) 3.5±0.1 168.2±4.6 3.4±0.1 153.2±5.0 
Vitamin D3 intake (IU D3/g 
b.wt./d) 
0.152±0.005 7.759±0.239 0.195±0.007 8.574±0.269 
Body weight (g)* 23.1±0.4 21.8±0.6 17.6±0.3 17.9±0.4 
AI, adequate intake, n=23; HiD, high vitamin D3, n=18; b.wt.: body weight. 
HiD females consumed 11% less absolute feed (P = 0.041) and 12% less feed corrected 
for body weight vs. AI females (P=0.020). HiD males consumed 4% less absolute feed 
vs. AI males (P = 0.047). HiD males consumed 10% more absolute feed (P = 0.042) but 
10% less feed corrected for body weight (P = 0.037) vs. HiD females. Males (153.2±3.6 
mg/g b.wt./d) consumed 17% less food corrected for body weight vs. females (185.1±5.2 
mg/g b.wt./d) (P<0.0001). Males (22.5 ±0.4 g) had 27% higher body weight vs. females 
(17.8±0.2 g) (P<0.0001). HiD males had 22% higher body weight (P<0.0001) vs. HiD 
females. HiD males had 6% lower body weight (P = 0.081) vs. AI males. HiD mice 
(3.2±0.1 g) had 7% less absolute food intake vs. AI mice (3.5 ± 0.1 g) (P = 0.062). Data 
are means ±SEM.  
 
 
Tissue Collection 
At age 113 d, mice were sacrificed and spinal cords were harvested. The mice 
were placed under anaesthesia with gaseous isoflurane as the tissue was collected and 
placed in individual sterile polyethylene tubes for immediate freezing in liquid nitrogen. 
Samples were stored at -80˚C.  
Spinal Cord Homogenization 
Spinal cords were weighed, and minced with a glass-Teflon Port-Evenhejm 
homogenizer (5% wt/vol) in radioimmunoprecipitation assay (RIPA) buffer (1:20) 
containing 50 mM tris HCL 8.0 (Bioshop, TRS002.500, Burlington, Ontario), 150 mM 
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NaCl (BioBasic Canada, 7647145, Markham, Ontario), 0.1% SDS (Bioshop, 
SDS001.500, Burlington, Ontario), 0.5% sodium deoxycholate (Bioship, DCA333.50, 
Burlington, Ontario), 1% NP-40 (Thermo Scientific, 28324, Rockford, Illinois), 5 mM 
EDTA pH 8.0 (Bioshop, EDT001.500, Burlington, Ontario) and 1 mM PMSF (Sigma-
Aldrich, 93482, St. Louis, Missouri). The protease inhibitor cocktail (Roche, 
11836153001, Manheim, Germany) was added to the buffer in accordance to 
manufacturer’s instructions (1:100) prior to homogenization. Mouse spinal cord was 
homogenized for about 40 grinds using constant force to ensure consistency and 
homogeneity of samples. Homogenates were divided in roughly equal volumes in 
eppendorf tubes and were placed on a shaker at 4oC for 30 minutes. The homogenates 
were then centrifuged at (600 g) for 20 min at 4oC. The resulting supernatant was 
decanted, put into newly labeled eppendorf tubes and immediately stored at -80oC. The 
protein concentration was determined using the BCA Protein Assay technique  (43). The 
supernatant concentration was measured at 562 nm using an ultraviolet 
spectrophotometer (Cecil 9200 Super Aquarius, Cambridge, UK). Protein concentrations 
were presented as mg/ml.  
Western Blot  
Equal amounts of protein were size-separated by 12.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to nitrocellulose 
membranes (#165-3322, Bio-Rad Mini-PROTEAN 2 electrophoresis system, 
Mississauga, ON, Canada) at 100 V for 2 h. The membranes were blocked in 3% fat free 
milk (SMI-36), 5% fat free milk (SOD2, catalase, TNF-α, IL-6) or 5% BSA (4-HNE, 3-
NY, GPx1, IL-10, Bax, Bcl-2, pro-caspase 3, cleaved caspase 3, GDNF, ChAT, SMI-32)  
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diluted in Tris-buffered saline with tween (1%) for 2 h at room temperature and incubated 
with primary antibodies in 3% fat free milk (SMI36), 5% fat free milk (catalase, TNF- α, 
IL-6), 1% BSA (SOD2, cleaved caspase 3, GNDF, ChAT), 3% BSA (IL-10, SMI32) or 
5% BSA (4-HNE, 3-NY, GPx1, Bax, Bcl-2, pro-caspase 3) against 4-HNE (1:800; 
Abcam, ab46545), 3-NY (1:1000; Abcam, ab110282), SOD2 (1:8000; Abcam, ab13533), 
catalase (1:3500; Abcam, ab1877-10), GPx1 (1:800; Abcam, 22604), TNF- α (1:2000; 
Abcam, ab9739) IL-6 (1:1000; Abcam, ab6672), IL-10 (1:2000; Abcam, ab9969), Bax 
(1:1000; Cell Signaling Technology, 2772), Bcl-2 (1:1000; Cell Signaling Technology, 
2870), pro-caspase 3 (1:1000; Millipore, 04-440), cleaved caspase 3 (1:1000; Millipore, 
04-439), GDNF (1:1000; Abcam, a18956), ChAT (1:1000; Abcam, ab85609), SMI-32 
(1:1000; Abcam, ab28029) and SMI-36 (1:1000; Abcam, ab24572), overnight at 4oC. 
Equal loading was verified by ponceau staining, as well as probing for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 1:100,000; MAB374, Millipore). The antigen-
antibody complexes were detected by incubating the membranes in anti-rabbit (1: 5000; 
Novus Biologicals, NB730-H) or anti-mouse (1:5000; Novus Biologicals, NB7539) HRP 
conjugated secondary antibodies at room temperature for 2 h in 3% fat free milk 
(SMI36), 5% fat free milk (4-HNE, catalase, TNF- α, IL-6), 1% BSA (SOD2, cleaved 
caspase 3, GDNF, ChAT), 3% BSA (IL-10, SMI32) or 5% BSA (3-NY, GPx1, Bax, Bcl-
2, pro-caspase 3). Immunoreactive proteins were visualized with enhanced 
chemiluminescence (sc-2048, Santa Cruz Biotechnology), and scanned using Kodak 
Imaging Station 4000MM Pro (Carestream Health, Inc. Rochester, NY, USA). Protein 
intensity was standardized to GAPDH and analyzed using Carestream MI (v 5.0.2.30, 
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NY, USA). Representative western blot bands for the biomarkers are found in 
supplementary figure S1.1 in Appendix A.  
Calculations 
Human equivalent dosage (HED) was calculated according to the US FDA  (44): 
HED = Animal dose (mg/kg) × [animal weight (kg) ÷ human weight (kg)]0.33. 
Statistical analysis  
We established planned comparisons between HiD vs. AI. A one-tailed 
independent t-test was used to determine differences between the diets within each sex, 
because we hypothesized a priori that absolute and body weight-adjusted spinal cord 
weight, antioxidant activity, neurotrophic factors and neuronal count would be higher in 
HiD males vs. AI but not females whereas oxidative damage, inflammation and apoptosis 
would be lower in HiD males vs. AI but not females. These are based on studies 
conducted by us and other researchers  (23, 29, 34, 36-41, 45-49). For all other outcome 
measures, a two-tailed analysis was performed. All statistical analyses were completed 
using GraphPad Prism 6 for Macintosh (GraphPad Software Inc, La Jolla, CA). Data 
were presented as means ± standard error of mean (SEM). Significance was set to P ≤ 
0.10, since this was a pilot study.  
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Results 
Oxidative Damage 
4-HNE 
There was no significant difference in 4-HNE protein content between the diets or 
between the sexes (Figure 1.1A and 1.1B). 
3-NY 
HiD females had 14% higher 3-NY protein content vs. AI females (P = 0.065) (Figure 
1.1C). HiD males had 16% lower 3-NY protein content vs. AI males (P = 0.073) (Figure 
1.1D). AI males had 18% higher 3-NY protein content vs. AI females (P = 0.073). HiD 
males had 14% lower 3-NY protein content vs. HiD females (P = 0.069).  
Antioxidant Enzymes 
SOD2 
There was no significant difference in SOD2 protein content between the diets or 
between the sexes (Figure 1.2A and 1.2B) 
Catalase 
HiD mice had 12% lower catalase protein content vs. AI (P = 0.097). HiD females had 
21% lower catalase protein content vs. AI females (P < 0.0001) (Figure 1.2C). HiD males 
had 34% higher catalase protein content vs. HiD females (P = 0.013). 
GPx1 
HiD mice had 13% higher GPx1 protein content vs. AI (P = 0.088). HiD females had 
18% higher GPx1 protein content vs. AI females (P = 0.101) (Figure 1.2E). AI males had 
10% higher GPx1 protein content vs. AI females (P = 0.054). 
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Inflammation 
TNF- α 
HiD mice had 16% higher TNF-α protein content vs. AI (P = 0.015). HiD females had 
21% higher TNF-α protein content vs. AI females (P = 0.003) (Figure 1.3A). 
Il-6 
HiD males had 24% lower IL-6 protein content vs. AI males (P = 0.085) (Figure 1.3D). 
AI males had 14% lower IL-6 protein content vs. AI females (P = 0.075). HiD males had 
38% lower IL-6 protein content vs. HiD females (P = 0.034). 
IL-10 
HiD females had 13% lower IL-10 protein content vs. AI females (P = 0.042) (Figure 
1.3E). AI males had 11% lower IL-10 protein content vs. AI females (P = 0.074). 
Apoptosis 
Bax 
There was no significant difference in Bax protein content between the diets or between 
the sexes. (Figure 1.4A and 1.4B).  
Bcl-2 
There was no significant difference in Bcl-2 protein content between the diets (Figure 
1.4C and 1.4D). AI males had 14% higher Bcl-2 protein content vs. AI females (P = 
0.048). 
Bax/Bcl-2 ratio 
There was no significant difference in Bax/Bcl-2 protein content between the diets or 
between the sexes (Figure 1.4E and 1.4F).  
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Caspase 3  
Pro-caspase 3 
HiD mice had 12% higher pro-caspase 3 protein content vs. AI (P = 0.003). HiD males 
had 22% higher pro-caspase 3 protein content vs. AI males (P = 0.036) (Figure 1.5B). 
HiD males had 17% higher pro-caspase 3 protein content vs. HiD females (P = 0.095). 
Cleaved caspase 3 
HiD females had 15% higher cleaved caspase 3 protein content vs. AI females (P = 
0.014) (Figure 5C). HiD males had 12% lower cleaved caspase 3 protein content vs. AI 
males (P = 0.063) (Figure 5D). HiD males had 27% lower cleaved caspase 3 protein 
content vs. HiD females (P < 0.001). 
Cleaved/pro-caspase 3 
HiD females had 13% higher cleaved/pro-caspase 3 protein content vs. AI females (P = 
0.010) (Figure 1.5E). HiD males had 26% lower cleaved/pro-caspase 3 protein content 
vs. AI males (P = 0.009) (Figure 1.5F). HiD males had 35% lower cleaved/pro-caspase 3 
vs. HiD females (P < 0.0001). 
Neurotrophic Factor 
GDNF 
There was no significant difference in GDNF protein content between the diets or 
between the sexes (Figure 1.6A and 1.6B).  
Neuron Damage 
ChAT 
HiD females had 18% lower ChAT protein content vs. AI females (P = 0.024) (Figure 
1.7A). AI males had 23% lower ChAT protein content vs. AI females (P = 0.005) 
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SMI-32 
There was no significant difference in SMI-32 protein content between the diets (Figure 
1.7C and 1.7D). AI males had 15% lower SMI-32 protein content vs. AI females (P = 
0.039). 
SMI-36 
There was no significant difference in spinal cord SMI-36 protein content between the 
diets (figure 1.7E and 1.7F). AI males had 13% lower spinal cord SMI-36 protein content 
vs. AI females (P = 0.016). HiD males had 13% lower SMI-36 vs. HiD females (P = 
0.008). 
SMI-36/SMI-32 
HiD males had 19% lower spinal cord SMI-36/SMI-32 protein content vs. AI males (P = 
0.098) (Figure 1.7H).  
Spinal cord weights 
Absolute spinal cord weight was not different between the diets (Table 1.3). Between the 
sexes, AI males had 15% lighter absolute spinal cord weight vs. AI females (P = 0.065) 
(Table 1.3). HiD males had 19% heavier body weight-adjusted spinal cord weight vs. AI 
males (P = 0.076) (Table 1.3; Figure 8B). Between the sexes, AI males had 33% lighter 
body weight-adjusted spinal cord weight vs. AI females (P = 0.001) (Table 1.3; Figure 
8C), and HiD males had 18% lighter body weight-adjusted spinal cord weight vs. HiD 
females (P = 0.045) (Table 1.3; Figure 8D).  
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Figure 1.1 Oxidative damage in HiD vs. AI G93A mice.  
4-HNE (A and B) and 3-NY (C and D) protein content (arbitrary units; AU) in spinal 
cord of 41 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) 
and 18 high vitamin D3 intake (HiD; 50 IU D3/g feed; 10 M, 8 F). 4-Hydroxynonenal (4-
HNE, A and B): There was no significant difference in 4-HNE protein content between 
the diets or between the sexes. 3-Nitrotyrosine (3-NY, C and D): HiD females had 14% 
higher 3-NY protein content vs. AI females (P = 0.065). HiD males had 16% lower 3-NY 
protein content vs. AI males (P = 0.073). AI males had 18% higher 3-NY protein content 
vs. AI females (P = 0.073). HiD males had 14% lower 3-NY protein content vs. HiD 
females (P = 0.069). Data presented as means ± SEM.   	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Figure 1.2 Antioxidant enzymes in HiD vs. AI G93A mice.  
SOD2 (A and B), catalase (C and D) and GPx1 (E and F) protein content (arbitrary units; 
AU) in spinal cord of 41 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 
12 M, 11 F) and 18 high vitamin D3 intake (HiD; 50 IU D3/g feed; 10 M, 8 F). SOD2 (A 
and B): There was no significant difference in SOD2 protein content between the diets or 
between the sexes. Catalase (C and D): HiD mice had 12% lower catalase protein 
content vs. AI (P = 0.097). HiD females had 21% lower catalase protein content vs. AI 
females (P < 0.0001). HiD males had 34% higher catalase protein content vs. HiD 
females (P = 0.013). GPx1 (E and F): HiD mice had 13% higher GPx1 protein content 
vs. AI (P = 0.088). HiD females had 18% higher GPx1 protein content vs. AI females (P 
= 0.101). AI males had 10% higher GPx1 protein content vs. AI females (P = 0.054). 
Data presented as means ± SEM.	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Figure 1.3 Inflammation in HiD vs. AI G93A mice.  
TNF-­‐α (A and B), IL-6 (C and D) and IL-10 (E and F) protein content (arbitrary units; 
AU) in spinal cord of 41 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 
12 M, 11 F) and 18 high vitamin D3 intake (HiD; 50 IU D3/g feed; 10 M, 8 F). TNF-α (A 
and B): HiD mice had 16% higher TNF-α protein content vs. AI (P = 0.015). HiD 
females had 21% higher TNF-α protein content vs. AI females (P = 0.003). IL-6 (C and 
D): HiD males had 24% lower IL-6 protein content vs. AI males (P = 0.085). AI males 
had 14% lower IL-6 protein content vs. AI females (P = 0.075). HiD males had 38% 
lower IL-6 protein content vs. HiD females (P = 0.034). IL-10 (E and F): HiD females 
had 13% lower IL-10 protein content vs. AI females (P = 0.042). AI males had 11% 
lower IL-10 protein content vs. AI females (P = 0.074). Data presented as means ± SEM. 
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Figure 1.4 Bax/Bcl-2 in HiD vs. AI G93A mice.  
Bax (panel A and B), Bcl-2 (C and D) and Bax/Bcl-2 ratio (panel E and F) protein 
content (arbitrary units; AU) in spinal cord of 41 G93A mice: 23 adequate vitamin D3 
intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 intake (HiD; 50 IU D3/g 
feed; 10 M, 8 F). Bax (A and B): There was no significant difference in Bax protein 
content between the diets or between the sexes. Bcl-2 (C and D): There was no 
significant difference in Bcl-2 protein content between the diets. AI males had 14% 
higher Bcl-2 protein content vs. AI females (P = 0.048). Bax/Bcl-2 ratio (E and F): There 
was no significant difference in Bax/Bcl-2 protein content between the diets or between 
the sexes. Data presented as means ± SEM.	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Figure 1.5 Caspase 3 in HiD vs. AI G93A mice.  
Pro-caspase 3 (A and B), cleaved caspase 3 (C and D) and cleaved/pro-caspase 3 ratio (E 
and F) protein content (arbitrary units; AU) in spinal cord of 41 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 intake (HiD; 
50 IU D3/g feed; 10 M, 8 F). Pro-caspase 3 (A and B): HiD mice had 12% higher pro-
caspase 3 protein content vs. AI (P = 0.003). HiD males had 22% higher pro-caspase 3 
protein content vs. AI males (P = 0.036). HiD males had 17% higher pro-caspase 3 
protein content vs. HiD females (P = 0.095). Cleaved caspase 3 (C and D): HiD females 
had 15% higher cleaved caspase 3 protein content vs. AI females (P = 0.014). HiD males 
had 12% lower cleaved caspase 3 protein content vs. AI males (P = 0.063). HiD males 
had 27% lower cleaved caspase 3 protein content vs. HiD females (P < 0.001). 
Cleaved/pro-caspase 3 ratio (E and F): HiD females had 13% higher cleaved/pro-
caspase 3 protein content vs. AI females (P = 0.010). HiD males had 26% lower 
cleaved/pro-caspase 3 protein content vs. AI males (P = 0.009). HiD males had 35% 
lower cleaved/pro-caspase 3 vs. HiD females (P < 0.0001). Data presented as means ± 
SEM. 
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Figure 1.6 Neurotrophic factor in HiD vs. AI G93A mice.  
GDNF protein content (A and B) (arbitrary units; AU) in spinal cord of 41 G93A mice: 
23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 
intake (HiD; 50 IU D3/g feed; 10 M, 8 F). There was no significant difference in GDNF 
protein content between the diets or between the sexes. Data presented as means ± SEM.	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Figure 1.7 Neuron damage in HiD vs. AI G93A mice.  
ChAT (A and B), SMI-32 (C and D), SMI-36 (E and F) and SMI-36/SMI-32 ratio (G and 
H) protein content (arbitrary units; AU) in spinal cord of 41 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 intake (HiD; 
50 IU D3/g feed; 10 M, 8 F). ChAT (A and B): HiD females had 18% lower ChAT protein 
content vs. AI females (P = 0.024). AI males had 23% lower ChAT protein content vs. AI 
females (P = 0.005). SMI-32 (C and D): There was no significant difference in SMI-32 
protein content between the diets. AI males had 15% lower SMI-32 protein content vs. AI 
females (P = 0.039). SMI-36 (E and F): There was no significant difference in spinal cord 
SMI-36 protein content between the diets. AI males had 13% lower spinal cord SMI-36 
protein content vs. AI females (P = 0.016). HiD males had 13% lower SMI-36 vs. HiD 
females (P = 0.008). SMI-36/SMI-32 ratio (G and H): HiD males had 19% lower spinal 
cord SMI-36/SMI-32 protein content vs. AI males (P = 0.098). Data presented as means 
± SEM. 
  
 70 
 
Figure 1.8 Body weight-adjusted spinal cord weights at 113 d. 
Body weight-adjusted spinal cord weight (mg/g b.wt.) of 41 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 intake (HiD; 
50 IU D3/g feed; 10 M, 8 F). Between the diets (A and B): HiD males had 19% heavier 
body weight-adjusted spinal cord weight vs. AI males (P = 0.076). Between the sexes (C 
and D): AI males had 33% lighter body weight-adjusted spinal cord weight vs. AI 
females (P = 0.001), and HiD males had 18% lighter body weight-adjusted spinal cord 
weight vs. HiD females (P = 0.045). Data presented as means ± SEM.	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Table 1.3. Spinal cord weight between the diets and sexes at 113 d. 
Spinal cord 
weights 
 
Females 
 
Males 
 
Within-AI 
between-sex 
differences 
Within-HiD 
between-sex 
differences 
 AI HiD 
P 
value 
AI HiD 
P 
value 
P value P value 
Absolute spinal 
cord weight (mg) 
583±43 576±30 NS 494±37 546±48 NS P = 0.065 NS 
Body weight-
adjusted spinal 
cord weight (mg/g 
b.wt.) 
31±2 30±2 NS 21±2 25±2 
P = 
0.076 
P = 0.001 P = 0.045 
Data are means ± SEM. 
AI, adequate intake; HiD, high vitamin D3  
AI Males, n = 12; AI Females, n = 11 
HiD Males, n = 10; HiD Females, n = 8 
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Discussion 
We investigated the effects of dietary vitamin D3 supplementation at 50x the 
rodent AI on markers of oxidative damage, antioxidant enzymes, inflammation, 
apoptosis, growth factors and neuron damage in the spinal cord of G93A mice, a rodent 
model of ALS. Dietary D3 at 50x the AI improved disease pathophysiology in male mice 
by lowering protein damage, inflammation and apoptosis compared to AI males. On the 
contrary, females supplemented with 50x AI of D3 had reached the threshold of toxicity. 
HiD females had higher protein damage, lower antioxidant capacity and higher 
inflammation, apoptosis and neuron damage, compared to AI females. The optimal 
therapeutic dose of vitamin D3 differs between males and females.  
In the present study, females consuming 50 IU of vitamin D3/g feed may have 
reached the threshold of toxicity due to the exacerbation of their disease pathophysiology. 
In a mouse model of experimental autoimmune encephalymyelitis (EAE; a rodent model 
of multiple sclerosis- MS) consuming 40 IU/d of vitamin D3, females had ~67% greater 
calcitriol concentration vs. males 70-84 d post-supplementation despite having similar 
serum values  (50). The study also reported ~4 fold lower calcitriol deactivating enzyme 
(CYP24A1) mRNA transcripts in females compared to males. A synergy exists between 
vitamin D3 and estrogen, which is also found in the spinal cord. Estrogen causes estrogen 
receptor-mediated down-regulation of CYP24A1 transcription to increase net calcitriol 
concentration, and thus enhances vitamin D function. As well, estrogen up-regulates 
VDR to enhance vitamin D potency, and, in turn, calcitriol uses VDR-mediated up-
regulation of estrogen synthase to enhance endogenous estrogen synthesis  (51).   
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Many studies have shown that females have higher serum vitamin D3 levels 
compared to males  (52-54). Estrogen plays a strong role in stimulating calcitriol in 
females  (55-57). Gray et al showed that serum calcitriol levels fluctuate during the 
menstrual cycle, increasing 2-fold from the early follicular phase (low estrogen) to 
menstruation (high estrogen)  (56). Moreover, post-menopausal women have lower 
calcitriol levels compared to their pre-menopausal state  (57), but increase their status by 
>50% when subjected to estrogen therapy  (58, 59). In the CNS, basal calcitriol levels are 
higher in females vs. males, because of the females’ ability to synthesize more calcitriol  
(50). As such, the presence of estrogen indicates that therapeutic vitamin D levels must 
differ between males and females, and that a specific dosage in males does not have the 
same impact in females.   
Though calcitriol has many beneficial effects on motor neurons, toxic levels pose 
a great concern because it can result in hypercalcemia  (60) in a disease model that 
already suffers from intracellular hypercalcemia-induced damage. Despite the fact that 
vitamin D increases the activity of calcium buffering proteins such as calbindin d-28k 
and parvalbumin  (61, 62), toxicity can cause excessive calcium accumulation. A 
dysregulation in calcium homeostasis is toxic for motor neurons  (63), and in sALS 
patients intracellular calcium levels are well above normal  (64). In motor neurons, high 
intracellular calcium levels can increase free radical production  (65), which leads to 
neuron damage and subsequently death. It is important to investigate the influence of 
vitamin D analogs on ALS pathophysiology, given that analogs mimic the beneficial 
effects of vitamin D without the dangers of hypercalcemia (66). 
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Vitamin D plays an important role in protecting the cell from oxidative stress. 
Protein damage, marked by 3-NY protein content, was 16% lower in HiD males vs. AI 
males. Calcitriol is protective against ultraviolet ray-induced increases in 3-NY in 
keratinocytes  (67).  This is due to calcitriol’s ability to lower the formation of nitric 
oxide (NO) products and increase p53 protein, which aids in DNA repair  (68). 
Conversely, AI males had 18% higher 3-NY protein content vs. AI females. In females, 
17β-estradiol’s antioxidative effect reduces 3-NY immunoreactivity  (69). Brain cell 
cultures of mice exposed to 17β-estradiol significantly reduced 3-NY levels regardless of 
whether or not they were exposed to superoxide  (70). Estrogen inhibits nitric oxide 
synthase (NOS) activity, thereby reducing peroxynitrite and subsequently 3-NY 
generation  (71). However, HiD females had 14% higher 3-NY levels compared to HiD 
males, in accord with the presence of toxicity. Increased concentrations of 3-NY have 
been found in the spinal cord of both sALS and fALS patients  (72). In HiD females, 
heightened oxidative stress brought about by hypervitaminosis D increased protein 
damage as marked by elevated 3-NY protein content.  
In terms of antioxidant capacity, catalase was 21% lower in HiD females vs. AI 
females. Generally, catalase activity is high in the liver and kidneys, and low in the brain 
and skeletal muscle  (73). The sharp decrease in catalase in HiD females may be due to 
the increase in the pro-inflammatory TNF-α. A strong link between catalase and TNF- α 
has been observed  (74).  Catalase neutralizes the oxidative effects of free radicals, but 
when inflammation exceeds its capabilities, the enzyme no longer functions properly and 
thus tissue damage occurs (75). Yasmineh et al’s study on rats showed that injection of 
100 µg/kg/day of human recombinant TNF-α for 5 days decreased the catalase enzyme 
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activity of the liver between 21-56% when compared to rats without injections  (74). A 
study has shown that a decrease in catalase enzyme activity is due to a reduction in 
catalase protein  (76). Interestingly, our study showed a 21% increase in TNF- α and a 
21% decrease in catalase, corresponding to the pattern observed in the study by 
Yasmineh et al.  This increase in TNF- α also confirms the presence of heightened 
oxidative stress. In insulin-resistant adipocytes, reactive oxidative species (ROS) 
production is increased when treated with TNF- α  (77). A decrease in catalase may be a 
result of inflammation-induced damage to the peroxisomes, where most of the catalase 
resides. In rat liver, TNF- α suppresses protein expression of both catalase and 
peroxisomal proteins  (78). Singh et al showed that the spinal cord of EAE mice have 
impaired peroxisomal function due to increased inflammation (79). This was marked by 
37% reduction in catalase enzyme activity, underscoring the importance of peroxisome 
integrity to catalase function.  
There was 18% higher GPx1 protein content in HiD females vs. AI females. 
Under physiological conditions, vitamin D has an inverse relationship with GPx1 and a 
positive association with glutathione reductase (GR) activity  (80). This relationship is 
due to reduced glutathione’s (GSH) role in maintaining intracellular redox balance. 
Hence, increasing the activity of GR and decreasing GPx1 function allow vitamin D to 
enhance the GSH pool. Thus, an upregulation of GPx1 activity may be an indicator of 
excessive cellular damage. Female hypertensive Wister rats had increased GPx1 activity 
and lower GSH levels  (81). In many cancers, GPx1 has been shown to further induce 
malignancy and promote tumor progression  (82). In breast cancer patients, high 
expression of GPx1 was associated with high rates of patient mortality and shorter overall 
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survival  (83). This may be due to nuclear factor-kappa B (NF-κB). In ALS, activated 
microglia use the NF-κB pathway to induce mitochondrial dysfunction inhibition of 
SOD2 and motor neuron death  (84, 85). When bound to the promoter region of GPx1, 
NF-κB upregulates its function and expression upstream  (82). Vitamin D and VDR 
inhibit NF-κB expression and thus decrease GPx1 levels (43, 44). In females, estrogen 
increases the conversion of calcidiol to calcitriol  (86), which heightens the ability of the 
vitamin to inhibit the NF-κB pathway, thereby reducing GPx1 levels. However, under 
toxic conditions, the excessive oxidative damage likely surpasses vitamin D’s ability to 
efficiently regulate GPx1. Toxicity, and thus heightened oxidative damage, may result in 
an adaptive increase in GPx1 levels to compensate for the elevated cellular damage.  The 
10% higher GPx1 levels in AI males vs. AI females indicate that at adequate non-toxic 
levels, vitamin D has a stronger ability in increasing GPx1 in males vs. females.  
As well as heightened inflammation, HiD females also had lower anti-
inflammatory cytokine, as marked by a 13% lower IL-10 compared to AI females. In 
patients with neuromyelitis optica, a CNS inflammatory syndrome, upregulation of 
oxidative stress resulted in lower IL-10 levels  (87). This indicates that a more 
inflammatory milieu is present in HiD females, likely due to the excessive oxidative 
stress brought about by hypervitaminosis D. Patients with advanced chronic heart failure, 
a disease marked by excessive inflammation, have a high TNF- α/IL-10 ratio  (88). This 
pattern was also observed in renal tissue of rats with systematic inhibition of NOS  (89). 
It is important to note that it is not NOS inhibition itself that downregulates IL-10 
production, but rather the subsequent deficiency in NO. NOS inhibition has been shown 
to reduce IL-10 levels, which lead to increases in TNF- α levels  (89), similar to our 
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observation in the current study. Normally, TNF- α is suppressed by IL-10 production, 
not NOS inhibition.  IL-10 knockout mice had increased endothelial NOS production 
which did not impact TNF-α levels  (89). The exact mechanistic link between IL-10 and 
NO has not been well established. Within the spinal cord, inhibition of NOS is important 
for neuroprotection and thus motor function of spinal cord injury (SCI) rats (90). NO-
related toxicity occurs when NOS produces NO that reacts with superoxide to produce 
peroxynitrite which nitrates tyrosine residues and upregulates 3-NY production  (91). 
Upregulation of 3-NY levels in HiD females in the current study may confirm the 
presence of NO-related toxicity.  In the CNS, calcitriol inhibits the synthesis of inducible 
NOS as a means of enhancing neuroprotection  (90). Despite the toxicity, the excessive 
calcitriol in the spinal cord of HiD females may have inhibited NOS as a means of 
reducing oxidative damage, resulting in lower IL-10 levels. The 11% lower IL-10 protein 
content in AI males compared to AI females may be an indicator that oxidative damage is 
higher in males, and hence NOS inhibition is higher, vs. females. Indeed, 3-NY and TNF- 
α protein levels were higher in AI males compared to AI females, suggesting higher 
susceptibility of AI males to neuron damage. 
HiD males had 24% lower IL-6 compared to AI males. Overall, males had lower 
IL-6 protein content compared to females, where AI and HiD males had 14% and 38% 
lower IL-6 levels, respectively, compared to their female counterparts. Studies show that 
testosterone maintains low IL-6 levels  (92-94). However, lower IL-6 protein content in 
HiD males vs. AI males indicates that vitamin D also reduces inflammation. Vitamin D 
downregulates IL-6 production in human monocytes  (95). 800 IU/d vitamin D3 
supplementation in colorectal adenoma patients showed a 32% decrease in plasma IL-6 
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levels  (96). Vitamin D’s action in lowering IL-6 levels may be mediated through its 
action on transforming growth factor beta (TGF-β1). TGF-β1 is a potent modulator of 
cell growth  (97).  Exogenous TGF-β1 protects neurons, including motor neurons, from 
damage occurring both in vitro and in vivo  (98).  TGF-β1 can reduce the inflammatory 
effects of IL-6 (99) by protecting neurons from Ca2+-mediated neural degeneration  
(100).  In EAE mice, supplementation with vitamin D3 increases the number of 
transcripts of TGF-β1 mRNA in affected CNS tissue  (101).  
With respect to apoptosis, opposing results were observed between the sexes. HiD 
females had 13% higher cleaved/pro-caspase 3 ratio compared to AI females, whereas 
HiD males had a 26% lower ratio compared to AI males. Consequently, HiD males had 
significantly lower apoptosis compared to HiD females. In HiD females, a higher ratio 
was due to a 15% increase in cleaved caspase 3. Hypervitaminosis D increases premature 
aging in mutant mice, a process associated with heightened oxidative stress  (102). In 
HiD females, greater 3-NY indicates the presence of oxidative stress.  High oxidative 
stress induces activation of caspase 3 in the spinal cord of mSOD1 mice  (103).  As well, 
excessive oxidative stress in HiD females may have led to glutathione depletion, due to 
high GPx1 levels, which is associated with activation of caspase 3  (104). In the high-
copy G93A mouse, depletion of GSH in the spinal cord and motor neurons correlates 
with apoptosis-inducing factor translocation, caspase-3 activation and motor neuron 
degeneration during disease onset and progression  (105). Conversely, HiD males had 
lower cleaved/pro-caspase 3 compared to AI males. Vitamin D has been shown to reduce 
activated caspase 3 in the spinal cord of EAE mice  (105). In HiD males, the 
downregulation of microglial activation, and thus oxidative damage and inflammation, 
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may have resulted in reduction of apoptosis. In cultured neurons of the rat hippocampus, 
vitamin D3 treatment lowered microglial activation by downregulating inflammation, 
marked by lower IFNγ and IL-1β levels  (106).  Calcitriol can also modulate oxidative 
stress by enhancing intracellular GSH pools to lower nitrite production  (107).  
With respect to neuron damage, HiD females had 18% lower ChAT compared to 
AI females. This may be due to higher peroxynitrite levels, marked by increased 3-NY 
levels. Cholinergic synaptosomes purified from Torpedo marmorata showed that 
peroxynitrite inhibits acetylcholine synthesis  (108). Interestingly, the inhibition of ChAT 
by peroxynitrite coincided with the appearance of nitrotyrosine and was evident at 
concentrations as low as 50-100 µM peroxynitrite. This confirms that damage and 
atrophy of motor neurons is strongly associated with nitration-induced protein damage. 
AI males had 23% lower ChAT and 15% lower SMI-32 compared to AI females, 
indicating higher neuron damage. In mSOD1 mice, onset, disease progression and 
survival are dependent on sex; males lose body weight more rapidly following disease 
onset and die before females (109, 110). A reduction in body weight reflects muscle 
atrophy brought about by neuron degeneration. As with higher motor neuron count in AI 
females, it is possible that damaged motor neurons are also more prevalent. This explains 
why SMI-36 levels were 13% lower in AI males vs. AI females. HiD males had 19% 
lower SMI-36/SMI-32 ratio, a proxy measure of motor neuron damage  (111), compared 
to AI males. With lower apoptosis, it is evident that motor neuron integrity is maintained, 
hence the lower SMI-36/SMI-32 ratio.  
On a tissue level, HiD males had 19% heavier body weight-adjusted spinal cord 
weights compared to AI males. This confirms vitamin D’s protective effects on a cellular 
 80 
level, retaining the integrity of the spinal cord and thus lowering the rate of degeneration. 
The protective effects of estrogen were also confirmed since both AI and HiD males had 
33% and 18% lighter body weight-adjusted spinal cord weight compared to their female 
counterparts, respectively. These results contrast with our previous study that found no 
difference in body weight-adjusted brain weights between the diets and sexes  (36). 
Correlational analysis showed that there was no association between body weight-
adjusted brain weights  (36) and body weight-adjusted spinal cord weights. This confirms 
that ALS pathology within the CNS is mainly localized to the spinal cord.  
This study outlines the beneficial effects of vitamin D at the molecular level in males at 
non-toxic dosages and the detrimental effects in females that reached the threshold of 
toxicity. The study also supports the attenuation of the decline in paw grip endurance 
(PaGE) in the HiD mice observed in our previous studies  (36, 37). It is important to note 
that females were not considered to be in a fully toxic state as previous studies in the 
same mouse model observed greater paw grip endurance (PaGE) compared to AI females  
(36). Supraphysiological concentrations of calcitriol in the spinal cord may have induced 
mild toxicity as evidenced by greater disease severity prior to onset and decreased food 
intake  (36).  As well, oxidative damage in the spinal cord of HiD females may explain 
the increase in Bax/Bcl2 ratio in the quadriceps of these mice compared to AI females  
(38).  However, the damaging effects of D3 toxicity in HiD females and the beneficial 
effects in HiD males were more exaggerated in the spinal cord than in the skeletal muscle 
of the same G93A mice  (38, 39). This is because vitamin D has a tissue-specific effect in 
the CNS vs. skeletal muscle, since calcidiol is the active vitamin D metabolite in skeletal 
muscle  (112), whereas in the CNS it is calcitriol  (113). Skeletal muscle cannot convert 
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calcidiol to calcitriol  (114). In the current study, HiD females consumed ~150 IU 
vitamin D3/d (8.6 IU/g b.wt./d), which seemed to induce hypercalcitriol toxicity both at 
the functional and cellular levels.  Functionally, there was greater disease severity prior to 
disease onset and decreased food intake  (36). Whereas at the cellular level, increased 
apoptosis was observed in the quadriceps of HiD females vs. AI females  (38), and in the 
spinal cord there was increased inflammation and apoptosis and lower antioxidant 
capacity. The improved PaGE in HiD mice is most probably due to the higher antioxidant 
capacity and lower inflammation in the quadriceps compared to AI mice.  G93A mice 
that were fed 10x AI vitamin D3/g feed not only had an improvement in their PaGE but 
also in their motor performance (37), corresponding to 8257 IU/d for an 80 kg man and 
8785 IU/d for a 70 kg woman. The vitamin D3 intake in this study corresponds to 40,037 
IU/d for an 80 kg man and 38,062 IU/d for a 70 kg woman. We previously hypothesized 
that the optimal therapeutic vitamin D dosage, both functionally and cellularly, lies 
between 10x and 50x AI vitamin D  (29, 36, 37). Karam et al’s retrospective study in 
ALS patients showed that supplementation with 2000 IU of vitamin D3/day for 9 months 
improved ALS functional rating scale score (ALSFRS-R)  (35). Based on our hypothesis 
and given the fact that there were no side effects in humans following supplementation 
with 10 000 IU/d dosages in patients with MS for 12 weeks  (115) and up to 40 000 IU/d 
for 28 weeks  (116), ALS patients in Karam et al’s study may have shown greater 
improvements in their ALSFRS-R had they been supplemented with dosages between 10 
000-40 000 IU/d.  
In conclusion, the present study demonstrates that at non-toxic levels, dietary 
vitamin D3 supplementation can lower oxidative damage, inflammation and apoptosis in 
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the G93A mouse model of ALS. However, when the threshold of toxicity is reached, 
disease pathophysiology is exacerbated. As well, there is a clear sexual dimorphism 
where at a similar high vitamin D dose females are at higher risk of reaching toxicity 
compared to males  (117).  
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Abstract 
Background: Dietary vitamin D3 (D3) restriction reduces paw grip endurance and motor 
performance in G93A mice, and increases inflammation and apoptosis in the quadríceps 
of females. ALS, a neuromuscular disease, causes progressive degeneration of motor 
neurons in the brain and spinal cord. 
Objective: We analyzed the spinal cords of G93A mice following dietary D3 restriction 
at 2.5% the adequate intake (AI) for oxidative damage (4-HNE, 3-NY), antioxidant 
enzymes (SOD2, catalase, GPx1), inflammation (TNF-α, IL-6, IL-10), apoptosis 
(bax/bcl-2 ratio, cleaved/pro-caspase 3 ratio), neurotrophic factor (GDNF) and neuron 
damage (ChAT, SMI-36/SMI-32 ratio). 
Methods: Beginning at age 25 d, 42 G93A mice were provided food ad libitum with 
either adequate (AI;1 IU D3/g feed; 12 M, 11 F) or deficient (DEF; 0.025 IU D3/g feed; 
10 M, 9 F) D3. At age 113 d, the spinal cords were analyzed for protein content. 
Differences were considered significant at P ≤ 0.10, since this was a pilot study. 
Results: DEF mice had 16% higher 4-HNE (P = 0.056), 12% higher GPx1 (P = 0.057) 
and 23% higher Bax/Bcl2 ratio (P = 0.076) vs. AI. DEF females had 29% higher GPx1 (P 
= 0.001) and 22% higher IL-6 (P = 0.077) vs. AI females. DEF males had 23% higher 4-
HNE (P = 0.066) and 18% lower SOD2 (P = 0.034) vs. AI males. DEF males had 27% 
lower SOD2 (P = 0.004), 17% lower GPx1 (P = 0.070), 29% lower IL-6 (P = 0.023) and 
22% lower ChAT (P = 0.082) vs. DEF females. 
Conclusion: D3 deficiency exacerbates disease pathophysiology in the spinal cord of 
G93A mice, the exact mechanisms are sex-specific. This is in accord with our previous 
results in the quadriceps, as well as functional and disease outcomes.  
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Introduction 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the 
most commonly occurring adult-onset motor neuron disease of unknown cause  (1, 2) and 
is typically diagnosed between 45 and 60 years of age  (3, 4). It is characterized by 
degeneration of upper and lower motor neurons, resulting in skeletal muscle atrophy  (5) 
and death by respiratory failure within 3-5 years of initial symptoms  (6-8).  90% of cases 
are of unknown etiology (sporadic ALS)  (3, 9), whereas the other 10% have inherited 
genetic mutations  (3, 10) (familial ALS), ~12% of these cases being a result of a 
mutation in the Cu2+/Zn2+ super-oxide dismutase 1 (SOD1) gene  (11-14). The most 
commonly used animal model of ALS is the G93A mouse model  (15) that transgenically 
overexpresses the mutant SOD1 gene  (10).  Their disease pathology and 
neurodegenerative patterns closely resemble that which is found in ALS patients  (10). 
On a cellular level, excessive stimulation of glutamate receptors  (16) leads to a large 
influx of calcium ion into the post synaptic neuron, resulting in a destructive cascade of 
membrane, cytoplasmic and nuclear events  (17). These include oxidative damage  (18, 
19), oxidative stress  (20, 21), inflammation  (22), compromised neurotrophic factor 
release (22) and apoptosis  (13). 
Some nutrition-based interventions have shown effectiveness in mitigating ALS 
disease severity in animal models of ALS  (23). Vitamin D is a fat-soluble vitamin with 
hormone-like properties that is essential for health, growth and development  (24). 
Vitamin D3 and/or its metabolites [calcidiol (25(OH)D3) and calcitriol (1,25(OH)2D3)] 
can protect dopaminergic neurons against the neurotoxic effects of glutamate and 
dopaminergic toxins  (25), and has anti-inflammatory and modulatory effects on CNS 
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components such as neurotrophins and growth factors (26).  Vitamin D treatment can 
improve compromised functional outcomes and muscle physiology in humans and 
rodents, whereas vitamin D receptor (VDR) knockout mice have loss of motor function 
and muscle mass (27). Vitamin D reduces the expression of biomarkers associated with 
oxidative stress and inflammation in diseases that share common pathophysiologies with 
ALS. Vitamin D deficiency has been associated with the development of inflammatory 
and immune diseases such as type II diabetes  (28), multiple sclerosis  (29), dementia and 
Alzheimer’s disease (30). A deficiency in vitamin D reduces the amount of calcium 
buffering protein, thus leading to higher lipid peroxidation and protein damage 	  (31). 
When investigating the effects of vitamin D on biomarkers of oxidative stress in obese 
children aged 7-14 y, obese children with 25(OH)D insufficiency (serum calcidiol <50 
nmol/L) had significantly elevated 3-nitrotyrosine (3-NY) levels, a marker of protein 
damage, vs. non-deficient obese children (serum calcidiol >50 nmol/L) (32). A partial 
correlation analysis showed an inverse relationship between 25(OH)D and 3-NY (r = -
0.424, P = 0.001). 
A retrospective study in ALS patients found that those with serum calcidiol levels 
<25 nmol/L increased their death rate by 6 fold and their rate of decline by 4 times, and 
were associated with a marked shorter life expectancy compared to patients with serum 
calcidiol levels >75 nmol/L  (33). We have previously demonstrated the detrimental 
effects of vitamin D3 restriction in the G93A mouse model of ALS  (34-37). Dietary 
vitamin D3 at 2.5% the adequate intake (AI) resulted in lower paw grip endurance (PaGE) 
and motor performance  (37), and in the quadriceps of female G93A resulted in increased 
inflammation  (35) and apoptosis  (36), when compared to their AI counterparts. 
 97 
Does vitamin D3 restriction directly impact the CNS? And, if it does, will vitamin 
D3 deficiency explain the functional outcomes in our previous study  (37). Hence, the 
objective of this study was to investigate the effects of vitamin D deficiency via dietary 
restriction (0.025 IU/g feed) vs. adequate intake (1 IU/g feed) on oxidative damage, 
antioxidant capacity, inflammation, apoptosis, neurotrophic factor and neuron damage in 
the spinal cord of the G93A transgenic mouse model of ALS.  
Methods 
Ethical Statement 
The experimental protocol used in this study followed the guidelines of the 
Canadian Council of Animal Care and was approved by York University Animal 
Research Ethics Board (protocol # 2007-9).  All the necessary steps were taken to 
minimize suffering and distress to the mice in the study.  
Animals 
Male B6SJL-TgN(SOD1-G93A)1Gur hemizygous mice (No. 002726) were 
harem-bred with non-affected female B6SJL control mice (No. 100012; Jackson 
Laboratory, Bar Harbor, ME). We identified the presence of the human-derived G93A 
transgene by using polymerase chain reaction (PCR) amplification of DNA extracted 
from ear tissue as outlined by Sigma-Aldrich (XNAT REDExtract-N-Amp Tissue PCR 
Kit; XNAT-1KT). All breeding mice were housed 3 females per 1 male, and consumed 
Research Diet AIN-93G (1 IU D3/g feed; Research Diet, New Brunswick, NJ). All 
animals were housed individually at age 25 d in a 12 h light/dark cycle.  
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Study Design 
42 (22 M, 20 F) G93A mice consumed a diet that contained an adequate intake of 
vitamin D3 (1 IU/g feed; Research Diet AIN-93G; Product # D10012G; Research Diets 
Inc, New Brunswick NJ [38]) ad libitum after weaning (21 d). At age 25 d, the mice were 
individually caged and divided into one of two groups: 1) adequate vitamin D3 (AI; 1 IU 
D3/g feed; 12 M, 11 F; Research Diet AIN-93G) or 2) deficient vitamin D3 (DEF; 1/40 IU 
D3/g feed; 10 M 9 F; Product #D10030801; Research Diets Inc, New Brunswick, NJ) 
(Table 1).  
When the mice reached a clinical score (CS; disease severity) of 3.0, food and 
calorie-free gel (Harlan-Gel, Harlan Teklad, Madison WI) were placed on the floor of the 
cage to fulfill ethics requirements. Endpoint was determined as previously described by 
Solomon et al 2011 (38). The calorie-free gel contained synthetic polymers (WATER 
LOCK® superabsorbent polymer G-400, G-430, G-500, G-530; 95% by weight) and 
methanol (4.5% by weight). A summary of food intake, vitamin D3 intake and body 
weight of the G93A mice can be found in Table 2.2.  Two researchers who were blinded 
to the diets conducted all measurements.  
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Table 2.1  Nutrient content of the adequate intake (AI) and deficient (DEF) vitamin D3 
diets 
Nutrient Diet 
 AI DEF 
Energy (kcal/g) 4 4 
Carbohydrate (%) 64 64 
Protein (%) 20 20 
Fat (%) 7 7 
Vitamin D3 (IU/g) 1a 0.025b 
Calcium (%) 0.5c 0.5d 
Vitamin mix V10037 (mg/g) 10 10 
Mineral mix S100022G (mg/g) 35 35 
 
Diets provided by Research Diets (based on AIN-93G; New Brunswick, NJ; AI 
product # D10012G; HiD product # D08080101;). 
a, included in vitamin mix V10037  
b, included in vitamin mix V13203  (39) 
c, included in mineral mix S100022G  (40) 
*  table adopted from Solomon et al, PLoS ONE 2011 (37).  
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Table 2.2 Food intake, vitamin D3 intake and body weight of G93A mice.   
Measurements Males Females 
 AI (n=12) DEF (n=10) AI (n=11) DEF (n=9) 
Food intake (g/d)* 3.5±0.1 4.2±0.3 3.4±0.1 3.3±0.1 
Food intake (mg/g 
b.wt./d)* 
151.5±5.4 188.3±12.9 195.0±6.7 182.2±6.4 
Vitamin D3 intake (IU 
D3/d) 
3.494±0.136 0.104±0.007 3.4±0.1 0.08±0.001 
Vitamin D3 intake (IU D3/g 
b.wt./d) 
0.1515±0.0054 0.0048±0.0004 0.1950±0.0067 0.0046±0.0002 
Body weight (g)* 23.1±0.4 22.1±0.6 17.6±0.3 18.1±0.4 
AI, adequate intake, n=23; DEF, deficient vitamin D3, n=19; b.wt.: body weight.  
DEF males consumed 19% more absolute feed (P = 0.038) and 24% more feed corrected 
for body weight (P = 0.011) vs. AI males. DEF males consumed 26% more absolute feed 
(P = 0.016) vs. DEF females. Males (168.2±7.5 mg/g b.wt./d) consumed 12% less feed 
corrected for body weight vs. females (189.2±4.8 mg/g b.wt./d) (P = 0.027). DEF males 
had 22% higher body weight vs. DEF females (P<0.0001). Males (22.7±0.4 g) had 27% 
higher body weight vs. females (17.9±0.2 g) (P<0.0001). Data are means ±SEM. 
 
Tissue Collection 
At age 113 d, mice were sacrificed and spinal cords were harvested. The mice 
were placed and kept under anesthesia with gaseous isoflurane as the tissue was collected 
and placed in individual sterile polyethylene tubes for immediate freezing in liquid 
nitrogen. Samples were stored at -80˚C.  
Spinal Cord Homogenization 
Spinal cords were weighed, and minced with a glass-Teflon Port-Evenhejm 
homogenizer (5% wt/vol) in radioimmunoprecipitation assay (RIPA) buffer (1:20) 
containing 50 mM tris HCL 8.0 (Bioshop, TRS002.500, Burlington, Ontario), 150 mM 
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NaCl (BioBasic Canada, 7647145, Markham, Ontario), 0.1% SDS (Bioshop, 
SDS001.500, Burlington, Ontario), 0.5% sodium deoxycholate (Bioship, DCA333.50, 
Burlington, Ontario), 1% NP-40 (Thermo Scientific, 28324, Rockford, Illinois), 5 mM 
EDTA pH 8.0 (Bioshop, EDT001.500, Burlington, Ontario) and 1 mM PMSF (Sigma-
Aldrich, 93482, St. Louis, Missouri). The protease inhibitor cocktail (Roche, 
11836153001, Manheim, Germany) was added to the buffer in accordance to 
manufacturer’s instructions (1:100) prior to homogenization. Mouse spinal cord was 
homogenized for about 40 grinds using constant force to ensure consistency and 
homogeneity of samples. Homogenates were divided in roughly equal volumes in 
eppendorf tubes and were placed on a shaker at 4oC for 30 minutes. The homogenates 
were then centrifuged at (600 g) for 20 min at 4oC. The resulting supernatant was 
decanted, put into newly labeled eppendorf tubes and immediately stored at -80oC. The 
protein concentration was determined using the BCA Protein Assay technique  (41). The 
supernatant concentration was measured at 562 nm using an ultraviolet 
spectrophotometer (Cecil 9200 Super Aquarius, Cambridge, UK). Protein concentrations 
were presented as mg/ml.  
Western Blot  
Equal amounts of protein were size-separated by 12.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to nitrocellulose 
membranes (#165-3322, Bio-Rad Mini-PROTEAN 2 electrophoresis system, 
Mississauga, ON, Canada) at 100 V for 2 h. The membranes were blocked in 3% fat free 
milk (SMI-36), 5% fat free milk (SOD2, catalase, TNF-α, IL-6) or 5% BSA (4-HNE, 3-
NY, GPx1, IL-10, Bax, Bcl-2, pro-caspase 3, cleaved caspase 3, GDNF, ChAT, SMI-32) 
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diluted in Tris-buffered saline with tween (1%) for 2 h at room temperature and incubated 
with primary antibodies in 3% fat free milk (SMI36), 5% fat free milk (catalase, TNF- α, 
IL-6), 1% BSA (SOD2, cleaved caspase 3, GNDF, ChAT), 3% BSA (IL-10, SMI32) or 
5% BSA (4-HNE, 3-NY, GPx1, Bax, Bcl-2, pro-caspase 3) against 4-HNE (1:800; 
Abcam, ab46545), 3-NY (1:1000; Abcam, ab110282), SOD2 (1:8000; Abcam, ab13533), 
catalase (1:3500; Abcam, ab1877-10), GPx1 (1:800; Abcam, 22604), TNF- α (1:2000; 
Abcam, ab9739) IL-6 (1:1000; Abcam, ab6672), IL-10 (1:2000; Abcam, ab9969), Bax 
(1:1000; Cell Signaling Technology, 2772), Bcl-2 (1:1000; Cell Signaling Technology, 
2870), pro-caspase 3 (1:1000; Millipore, 04-440), cleaved caspase 3 (1:1000; Millipore, 
04-439), GDNF (1:1000; Abcam, a18956), ChAT (1:1000; Abcam, ab85609), SMI-32 
(1:1000; Abcam, ab28029) and SMI-36 (1:1000; Abcam, ab24572), overnight at 4oC. 
Equal loading was verified by ponceau staining, as well as probing for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 1:100,000; MAB374, Millipore). The antigen-
antibody complexes were detected by incubating the membranes in anti-rabbit (1: 5000; 
Novus Biologicals, NB730-H) or anti-mouse (1:5000; Novus Biologicals, NB7539) HRP 
conjugated secondary antibodies at room temperature for 2 h in 3% fat free milk 
(SMI36), 5% fat free milk (4-HNE, catalase, TNF- α, IL-6), 1% BSA (SOD2, cleaved 
caspase 3, GDNF, ChAT), 3% BSA (IL-10, SMI32) or 5% BSA (3-NY, GPx1, Bax, Bcl-
2, pro-caspase 3). Immunoreactive proteins were visualized with enhanced 
chemiluminescence (sc-2048, Santa Cruz Biotechnology), and scanned using Kodak 
Imaging Station 4000MM Pro (Carestream Health, Inc. Rochester, NY, USA). Protein 
intensity was standardized to GAPDH and analyzed using Carestream MI (v 5.0.2.30, 
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NY, USA). Representative western blot bands for the biomarkers are found in 
supplementary figure S2.1 in Appendix B.  
Calculations 
Human equivalent dosage (HED) was calculated according to the US FDA  (40): 
HED = Animal dose (mg/kg) × [animal weight (kg) ÷ human weight (kg)]0.33. 
Statistical analysis  
We established planned comparisons between HiD vs. AI. A one-tailed 
independent t-test was used to determine differences between the diets within each sex, 
because we hypothesized a priori that absolute and body weight-adjusted spinal cord 
weight, antioxidant activity, neurotrophic factors and neuronal count would be higher in 
HiD males vs. AI but not females whereas oxidative damage, inflammation and apoptosis 
would be lower in HiD males vs. AI but not females. These are based on studies 
conducted by us and other researchers  (23,27,32,34-38,41-45). For all other outcome 
measures, a two-tailed analysis was performed. All statistical analyses were completed 
using GraphPad Prism 6 for Macintosh (GraphPad Software Inc, La Jolla, CA). Data 
were presented as means ± standard error of mean (SEM). Significance was set to P ≤ 
0.10, since this was a pilot study.  
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Results 
Oxidative Damage 
4-HNE 
DEF mice had 16% higher 4-HNE protein content vs. AI (P = 0.056). DEF males had 
23% higher 4-HNE protein content vs. AI males (P = 0.066) (Figure 2.1B). 
3-NY 
There was no significant difference in 3-NY protein content between the diets (Figure 
2.1C and 2.1D). AI males had 18% higher 3-NY protein content vs. AI females (P = 
0.073). Data presented as means ± SEM. 
Antioxidant Enzymes 
SOD2 
DEF males had 18% lower SOD2 protein content vs. AI males (P = 0.034) (Figure 2.2B). 
DEF males had 27% lower SOD2 protein content vs. DEF females (P = 0.004). 
Catalase 
There was no significant difference in catalase protein content between the diets or 
between the sexes (Figure 2.2C and 2.2D) 
GPx1 
DEF mice had 12% higher GPx1 protein content vs. AI (P = 0.057). DEF females had 
29% higher GPx1 protein content vs. AI females (P = 0.001) (Figure 2.2E). AI males had 
10% higher GPx1 protein content vs. AI females (P = 0.054). DEF males had 17% lower 
GPx1 protein content vs. DEF females (P = 0.070). 
Inflammation 
TNF- α 
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There was no significant difference in TNF-α protein content between the diets or 
between the sexes (Figure 2.3A and 2.3B). 
Il-6 
DEF females had 22% higher IL-6 protein content vs. AI females (P = 0.077) (Figure 
2.3C). AI males had 14% lower IL-6 protein content vs. AI females (P = 0.075). DEF 
males had 29% lower IL-6 protein content vs. DEF females (P = 0.023). 
IL-10 
There was no significant difference in IL-10 protein content between the diets (Figure 
2.3E and 2.3F). AI males had 11% lower IL-10 protein content vs. AI females (P = 
0.074).   
Apoptosis 
Bax 
There was no significant difference in Bax protein content between the diets or between 
the sexes (Figure 2.4A and 2.4B).  
Bcl-2 
There was no significant difference in Bcl-2 protein content between the diets (Figure 
2.4C and 2.4D). AI males had 14% higher Bcl-2 protein content vs. AI females (P = 
0.048). 
Bax/Bcl-2 ratio 
DEF mice had 23% higher Bax/Bcl-2 protein content vs. AI (P = 0.076). 
Caspase 3  
Pro-caspase 3 
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There was no significant difference in pro-caspase protein content between the diets or 
between the sexes (Figure 2.5A and 2.5B). 
Cleaved caspase 3 
There was no significant difference in cleaved caspase 3 protein content between the 
diets or between the sexes (Figure 2.5C and 2.5D). 
Cleaved/pro-caspase 3 
There was no significant difference in cleaved/pro-caspase 3 protein content between the 
diets or between the sexes (Figure 2.5E and 2.5F).  
Neurotrophic Factor 
GDNF 
There was no significant difference in GDNF protein content between the diets or 
between the sexes (Figure 2.6A and 2.6B).  
Neuron Damage 
ChAT 
There was no significant difference in ChAT protein content between the diets (Figure 
2.7A and 2.7B). AI males had 23% lower ChAT protein content vs. AI females (P = 
0.005).  DEF males had 22% lower ChAT protein content vs. DEF females (P = 0.082) 
SMI-32 
There was no significant difference in SMI-32 protein content between the diets (Figure 
2.7C and 2.7D). AI males had 15% lower SMI-32 protein content vs. AI females (P = 
0.039). DEF males had 17% lower SMI-32 protein content vs. DEF females (P = 0.046).   
SMI-36 
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There was no significant difference in SMI-36 protein content between the diets (Figure 
2.7E and 2.7F). AI males had 13% lower SMI-36 protein content vs. AI females (P = 
0.016). 
SMI-36/SMI-32 
There was no significant difference in SMI-36/SMI-32 protein content between the diets 
or between the sexes (Figure 2.7G and 2.7H). 
Spinal cord weights 
Absolute spinal cord weight was not different between the diets (Table 2.3). Between the 
sexes, AI males had 15% lighter absolute spinal cord weight vs. AI females (P = 0.065), 
and DEF males had 16% lighter absolute spinal cord weight vs. DEF females (P = 0.053) 
(Table 2.3). There was no significant difference in body weight-adjusted spinal cord 
weights between the diets (Table 2.3; Figure 8A and 8B). Between the sexes, AI males 
had 33% lighter body weight-adjusted spinal cord weight vs. AI females (P = 0.001) 
(Table 2.3; Figure 8C), and DEF males had 27% lighter body weight-adjusted spinal cord 
weight vs. DEF females (P = 0.005) (Table 2.3; Figure 8D).  
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Figure 2.1 Oxidative damage in DEF vs. AI G93A mice.  
4-HNE (A and B) and 3-NY (C and D) protein content (arbitrary units; AU) in spinal 
cord of 42 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) 
and 19 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; 10 M, 9 F). 4-
Hydroxynonenal (4-HNE, A and B): DEF mice had 16% higher 4-HNE protein content 
vs. AI (P = 0.056). DEF males had 23% higher 4-HNE protein content vs. AI males (P = 
0.066). 3-Nitrotyrosine (3-NY, C and D): There was no significant difference in 3-NY 
protein content between the diets. AI males had 18% higher 3-NY protein content vs. AI 
females (P = 0.073). Data presented as means ± SEM. 
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Figure 2.2 Antioxidant enzymes in DEF vs. AI G93A mice.  
SOD2 (A and B), catalase (C and D) and GPx1 (E and F) protein content (arbitrary units; 
AU) in spinal cord of 42 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 
12 M, 11 F) and 19 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; 10 M, 9 F). 
SOD2 (A and B): DEF males had 18% lower SOD2 protein content vs. AI males (P = 
0.034). DEF males had 27% lower SOD2 protein content vs. DEF females (P = 0.004). 
Catalase (C and D): There was no significant difference in catalase protein content 
between the diets or between the sexes. GPx1 (E and F): DEF mice had 12% higher 
GPx1 protein content vs. AI (P = 0.057). DEF females had 29% higher GPx1 protein 
content vs. AI females (P = 0.001). AI males had 10% higher GPx1 protein content vs. 
AI females (P = 0.054). DEF males had 17% lower GPx1 protein content vs. DEF 
females (P = 0.070). Data presented as means ± SEM. 
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Figure 2.3 Inflammation in DEF vs. AI G93A mice.  
TNF- α (A and B), IL-6 (C and D) and IL-10 (E and F) protein content (arbitrary units; 
AU) in spinal cord of 42 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 
12 M, 11 F) and 19 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; 10 M, 9 F). 
TNF-α (A and B): There was no significant difference in TNF-α protein content between 
the diets or between the sexes. IL-6 (C and D): DEF females had 22% higher IL-6 protein 
content vs. AI females (P = 0.077). AI males had 14% lower IL-6 protein content vs. AI 
females (P = 0.075). DEF males had 29% lower IL-6 protein content vs. DEF females (P 
= 0.023). IL-10 (E and F): There was no significant difference in IL-10 protein content 
between the diets. AI males had 11% lower IL-10 protein content vs. AI females (P = 
0.074).  Data presented as means ± SEM.  
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Figure 2.4 Bax/Bcl-2 in DEF vs. AI G93A mice. 
Bax (A and B), Bcl-2 (C and D) and Bax/Bcl-2 ratio (E and F) protein content (arbitrary 
units; AU) in spinal cord of 42 G93A mice: 23 adequate vitamin D3 intake (AI; 1 IU D3/g 
feed; 12 M, 11 F) and 19 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; 10 M, 9 
F). Bax (A and B): There was no significant difference in Bax protein content between 
the diets or between the sexes. Bcl-2 (C and D): There was no significant difference in 
Bcl-2 protein content between the diets. AI males had 14% higher Bcl-2 protein content 
vs. AI females (P = 0.048). Bax/Bcl-2 ratio (E and F): DEF mice had 23% higher 
Bax/Bcl-2 protein content vs. AI (P = 0.076). Data presented as means ± SEM.  
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Figure 2.5 Caspase 3 in DEF vs. AI G93A mice.  
Pro-caspase 3 (A and B), cleaved caspase 3 (C and D) and cleaved/pro-caspase 3 (E and 
F) protein content (arbitrary units; AU) in spinal cord of 42 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 19 deficient vitamin D3 intake 
(DEF; 0.025 IU D3/g feed; 10 M, 9 F). There was no significant difference in pro-caspase 
3, cleaved caspase 3 and cleaved/pro-caspase 3 protein content between the diets or 
between the sexes. Data presented as means ± SEM. 
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Figure 2.6 Neurotrophic factor in DEF vs. AI G93A mice.  
GDNF protein content (A and B) (arbitrary units; AU) in spinal cord of 42 G93A mice: 
23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 19 deficient vitamin 
D3 intake (DEF; 0.025 IU D3/g feed; 10 M, 9 F). There was no significant difference in 
GDNF protein content between the diets or between the sexes. Data presented as means ± 
SEM. 
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Figure 2.7 Neuron damage in DEF vs. AI G93A mice.  
ChAT (A and B), SMI-32 (C and D), SMI-36 (E and F) and SMI-36/SMI-32 ratio (G and 
H) protein content (arbitrary units; AU) in spinal cord of 42 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 19 deficient vitamin D3 intake 
(DEF; 0.025 IU D3/g feed; 10 M, 9 F). ChAT (A and B): There was no significant 
difference in ChAT protein content between the diets. AI males had 23% lower ChAT 
protein content vs. AI females (P = 0.005).  DEF males had 22% lower ChAT protein 
content vs. DEF females (P = 0.082). SMI-32 (C and D): There was no significant 
difference in SMI-32 protein content between the diets. AI males had 15% lower SMI-32 
protein content vs. AI females (P = 0.039). DEF males had 17% lower SMI-32 protein 
content vs. DEF females (P = 0.046).  SMI-36 (E and F): There was no significant 
difference in SMI-36 protein content between the diets. AI males had 13% lower SMI-36 
protein content vs. AI females (P = 0.016). SMI-36/SMI-32 ratio (G and H): There was 
no significant difference in SMI-36/SMI-32 protein content between the diets or between 
the sexes. Data presented as means ± SEM.  
 116 
 
 
Figure 2.8 Body weight-adjusted spinal cord weights at 113 d. 
Body weight-adjusted spinal cord weight (mg/g b.wt.) of 42 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 19 deficient vitamin D3 intake 
(DEF; 0.025 IU D3/g feed; 10 M, 9 F). Between the diets (A and B): There was no 
significant difference in body weight-adjusted spinal cord weights between the diets.  
Between the sexes (C and D): AI males had 33% lighter body weight-adjusted spinal cord 
weight vs. AI females (P = 0.001), and DEF males had 27% lighter body weight-adjusted 
spinal cord weight vs. DEF females (P = 0.005). Data presented as means ± SEM. 
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Table 2.3. Spinal cord weight between the diets and sexes at 113 d. 
Spinal cord 
weights 
 
Females 
 
Males  
Within-AI 
between-sex 
differences 
Within-DEF 
between-sex 
differences 
 AI DEF 
P 
value 
AI DEF 
P 
value 
 P value P value 
Absolute 
spinal cord 
weight (mg) 
583±43 581±33 NS 494±37 489±42 NS  P = 0.065 P = 0.053 
Body weight-
adjusted 
spinal cord 
weight (mg/g 
b.wt.) 
31±2 30±5 NS 21±2 22±7 NS  P = 0.001 P = 0.005 
Data are means ± SEM. 
AI, adequate intake; DEF, deficient vitamin D  
AI Males, n = 12; AI Females, n = 11 
DEF Males, n = 10; DEF Females, n = 9 	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Discussion 
We investigated the effects of vitamin D deficiency, via dietary vitamin D3 
restriction equivalent to 2.5% the rodent AI, on markers of oxidative damage, antioxidant 
enzymes, inflammation, apoptosis, growth factors and neuron damage in the spinal cord 
of G93A mice, a rodent model of ALS.  Dietary vitamin D restriction at 1/40th AI 
exacerbates disease pathophysiology as DEF mice displayed higher levels of lipid 
peroxidation and apoptosis compared to AI. DEF females had higher inflammation and a 
compensatory increase in the antioxidant GPx1 compared to AI females. Conversely, 
DEF males had reduced antioxidant capacity compared to AI males.  When comparing 
differences between the sexes, DEF males had lower antioxidant enzymes and neuronal 
count compared to DEF females. The extant sexual dimorphism both in AI and DEF mice 
confirms that though detrimental, vitamin D deficiency negatively impacts different 
pathways depending on the sex, having a more deleterious effect in males compared to 
females. 
 Sexual dimorphism was observed in our current study as vitamin D deficiency 
caused differential results in males vs. females. Sexual dimorphism exists in a multitude 
of neurological and mental disorders such as multiple sclerosis (MS), Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and ALS  (27). ALS is predominant in males, but 
with increasing age the ratio of male-to-female diagnoses becomes smaller. The sex 
difference may be a result of different aromatase activity, the enzyme that converts 
testosterone into estradiol. This activity is neuroprotective  (42, 43) and is higher in 
cortical female astrocytes than cortical male astrocytes  (44). The dimorphic nature of the 
enzyme can protect astrocytes, as well as other CNS cell types such as neurons, from 
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damage in females. It has also been postulated that the presence of the sex hormone 
estrogen plays a role in this dimorphism. Recent clinical evidence has shown that 
estrogen treatment reduces the risk and delays the onset of many neurodegenerative 
diseases  (45).  In primary cultures of Wistar rat spinal cord, estradiol exerts 
neuroprotective effects in vivo  (46). In vitro, estradiol protects cerebral neurons against 
glutamate excitotoxicity  (46). Administration of the phytoestrogen genistein to male 
mSOD1 mice reduces the difference in disease onset and mortality between the sexes 
(prior to genistein administration, disease onset and mortality were reached sooner in 
males vs. females), confirming the strong role of sex hormones  (47). Ovariectomy of 
G93A mice accelerates disease progression, and a high-dose of 17β-estradiol 
significantly slows down disease progression in these mice  (48) In the presence of 
vitamin D3, estrogen synthesis is increased  (49), allowing both estrogen and vitamin D3 
to exert neuroprotective effects. A confirmed synergy exists between vitamin D3 and 
estrogen, which is also found in the spinal cord  (50). Estrogen causes estrogen receptor-
mediated down-regulation of CYP24A1 (calcitriol deactivating enzyme) transcription to 
increase net calcitriol concentration, and thus enhance vitamin D function  (50). As well, 
estrogen up-regulates VDR to enhance vitamin D potency, and, in turn, calcitriol causes 
VDR-mediated up-regulation of estrogen synthase to enhance endogenous estrogen 
synthesis  (51).  As a result, basal CNS calcitriol levels are higher in females vs. males  
(52).  
A deficiency in vitamin D reduces the amount of calcium buffering protein, thus 
leading to higher lipid peroxidation  (31). This explains why DEF males had 23% higher 
4-HNE protein content, a marker of oxidative damage, vs. AI males. This difference was 
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not observed in DEF females vs. AI. This is due to estrogen’s protective role. Co-
exposure of 17β-estradiol and 4-HNE in PC12 cell lines showed that estrogen was 
significantly effective against the cytotoxic response of 4-HNE  (53). This is because 
17β-estradiol has the ability to stabilize mitochondrial potential against oxidative stress  
(54). As well, estrogen works similarly to vitamin D to establish cellular calcium 
homeostasis. Chronic 17β-estradiol treatment represses glutamate receptor-mediated Ca2+ 
influx (55). In ALS, a disruption of calcium transport can form free radicals that cause 
lipid peroxidation in the cell (56). Vitamin D induces the synthesis of proteins such as 
parvalbumin that help maintain cellular calcium homeostasis  (57), thus lowering lipid 
peroxidation, in diabetic rats (58). Vitamin D also reduces malondialdehyde (MDA), a 
marker of lipid peroxidation, by stimulating the gene expression of calcium buffering 
proteins calbindin-D28k and calbindin-d9k  (31).  Obese children deficient in vitamin D 
(serum calcidiol <50 nmol/L) had higher lipid peroxidation as marked by increased 3-NY 
and MDA levels compared to non-deficient obese children (serum calcidiol >50 nmol/L)  
(32).  
The protective role of estrogen is also a factor in why AI males had 18% higher 3-
NY protein content vs. AI females. 17β-estradiol’s antioxidative effect reduces 3-NY 
immunoreactivity  (59). Brain cell cultures of mice exposed to 17β-estradiol significantly 
reduced 3-NY levels regardless of whether or not they have been exposed to superoxide  
(60). Estrogen can directly inhibit nitric oxide synthase (NOS) activity, thereby reducing 
peroxynitrite and subsequently 3-NY generation  (61).  
 Vitamin D deficiency also had a negative impact on antioxidant capacity. SOD2 
was 18% lower in DEF males vs. AI males. Compared to healthy individuals, SOD2 
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activity is lower in the brain and spinal cord of ALS patients (62). It is normally expected 
that in response to higher oxidative damage, antioxidant capacity increases. Thus, the 
exact mechanism that leads to a reduction in SOD2 activity is not well understood. It is 
possible that the loss of activity could be a result of post-translational modification. 
During CNS injury, nitric oxide (NO) is released at a high rate, which reacts with 
superoxide and leads to the production of nitrogenous species such as peroxynitrite 
(ONOO-)  (63).  Peroxynitrite, which is highly prevalent in ALS spinal cord, is the only 
known biological oxidant to inactivate enzymatic activity, nitrate important tyrosine 
residues and cause dityrosine formation in SOD2  (64).  Higher levels of peroxynitrite 
lead to increased production of 3-NY  (65). Compared to their female counterparts, AI 
and DEF males had 18% and 6% higher 3-NY levels, respectively, which could explain 
why SOD2 was lower in DEF males, but not DEF females, vs. AI. A reduction in SOD2 
in DEF males may be related to vitamin D’s impact on nuclear factor-kappa B (NF-κB). 
In ALS, activated microglia use the NF-κB pathway to induce mitochondrial dysfunction 
inhibition of SOD2 and motor neuron death  (66, 67). NF-κB leads to mitochondrial 
dysfunction inhibition of SOD2 through nitration, by activating inducible NOS (iNOS)  
(68). The local conversion of calcidiol to calcitriol in the CNS is a neuroprotective 
response that inhibits NF-κB-related iNOS induction  (69). Without the protective effects 
of vitamin D, this neuroprotection diminishes, which may explain the lower levels of 
SOD2 in DEF males.  
 GPx1 was 29% higher in DEF females vs. AI females. Female hypertensive 
Wister rats have shown increased GPx1 activity and lower reduced glutathione (GSH) 
levels  (70). Under physiological conditions, vitamin D has an inverse relationship with 
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GPx1 activity and a positive association with glutathione reductase (GR) activity  (71). 
This relationship is due to GSH’s role in maintaining intracellular redox balance. 
Increasing the activity of GR and decreasing GPx1 function allow vitamin D to enhance 
the GSH pool. In vitamin D deficiency however, excessive inflammation, as reflected by 
high IL-6 levels, increases GPx1 activity as a means of reducing oxidative protein injury  
(72). This also explains why, in this study, DEF females did not have a significant 
increase in 3-NY vs. AI. Vitamin D deficiency increased IL-6 levels by 22% compared to 
AI females, thereby elevating GPx1 protein content by 29%. Thus, the adaptive increase 
in GPx1 may indicate heightened inflammation and cellular damage. In many cancers, 
including esophageal cancer, GPx1 further induces malignancy and promotes tumor 
progression, effects that can be reduced by vitamin D  (73). In breast cancer patients, high 
expression of GPx1 was associated with high rate of patient mortality and shorter overall 
survival  (74), which may be due to NF-κB. When bound to the promoter region of GPx1, 
NF-κB upregulates its function and expression upstream  (73). Vitamin D and VDR 
inhibit NF-κB expression and thus decrease GPx1 levels  (75). In females, estrogen’s 
ability to convert calcidiol to calcitriol  (76) can heighten the ability of the vitamin to 
inhibit the NF-κB pathway, thereby reducing GPx1 levels. This may explain why AI 
males had 10% higher GPx1 protein content than AI females. 
IL-6 levels were 22% higher in DEF females vs. AI females. Damage to the CNS 
causes an upregulation in IL-6 and other pro-inflammatory cytokines such as TNF-α  
(77). IL-6 plays a great role in astrocyte and microglia activation, microglial proliferation 
as well as gliosis  (78). Though it is meant to repair, gliosis can work as a double-edged 
sword: it can produce neurotrophic factors and protect the CNS from toxins, but it can 
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also produce neurotoxins such as nitric oxide, an important factor in free-radical genesis  
(78). Estrogen is known to regulate IL-6 expression in different cell types  (79). In biliary 
epithelial cells, estrogen had the ability to stimulate IL-6 production in both the 
neoplasmic and non-neoplasmic cells that expressed estrogen receptor alpha  (79). A 
study on the effects of gonadal steroids on IL-6 in peripheral blood mononuclear cells 
showed that 17β-estradiol promotes IL-6 production and release  (80). As well, 
deficiency in vitamin D after trauma puts women at a greater risk of elevated IL-6 levels  
(81). This is in accord with Miller et al’s study that showed that women with serum 
25(OH)D levels of <37.5 nmol/L at the time of hip fracture had higher serum IL-6 levels 
in the year after the hip fracture (81). Alternatively, testosterone maintains low IL-6 
levels  (82-84). This explains why we observed 14% lower IL-6 in AI males vs. AI 
females, and 29% lower IL-6 in DEF males vs. DEF females. Interestingly, testosterone 
is also negatively associated with TNF-α  (84), whereas estradiol increases its expression  
(85). AI and DEF males had non-significant 4% and 12% lower TNF-α levels vs. their 
female counterparts. Higher TNF-α levels in DEF females reflects vitamin D’s impact on 
this inflammatory cytokine. In females, a significant inverse association exists between 
25(OH)D and TNF-α, whereby vitamin D deficiency increases levels of the inflammatory 
cytokine (86). A study in endurance-trained athletes showed that circulating TNF-α does 
not increase linearly with decreasing 25(OH)D concentration. Instead, it is abruptly 
higher in those that are vitamin D deficient (lower than 80 nmol/L)  (87). In neuron and 
glial cells, matrix metalloproteinase-9 (MMP-9) regulates TNF-α levels and is found in 
high levels in damaged ALS motor neurons  (88). MMPs are largely associated with 
inflammation and work to remodel and break down the extracellular matrix and regulate 
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leukocyte migration within it. Calcitriol reduces MMP-9 activity, thereby reducing TNF-
α levels  (89). Within the spinal cord of G93A mice, upregulation of the p38 mitogen 
activated protein kinase (p38MAPK), a signaling pathway responsible for cell death, is 
associated with the upregulation of TNF-α receptors  (90). Calcitriol reduces p38MAPK 
activity, thereby reducing TNF- α levels  (91, 92). In terms of anti-inflammatory 
cytokines, AI males had 11% lower IL-10 protein content vs. AI females. IL-10 has been 
shown to increase in the presence of estrogen  (93). Malaria infected female mice were 
shown to have higher IL-10 levels compared to males  (94).  In terms of its relationship 
with inflammatory cytokines, higher IL-6 levels induce IL-10 production  (95). This 
explains why the higher IL-10 levels we observed in females were commensurate with 
higher IL-6 protein content.  
There was 23% higher Bax/Bcl-2 in DEF mice vs AI mice. However, this may not 
necessarily indicate that apoptosis was prevalent. This is because no changes in activated 
caspase 3 and neuron damage were observed between the diets. Though Bax/Bcl-2 ratio 
was elevated in DEF mice, the increase was not sufficient enough to activate caspase 3, 
the effector molecule in the apoptotic pathway. High Bax/Bcl-2 ratio increases the 
vulnerability of neurons to apoptosis  (96), and is observed in neuromuscular disorders 
such as ALS  (97). What this may indicate is that apoptotic proteins can reduce neuronal 
viability without leading to large-scale apoptosis. This is also confirmed in our previous 
study in HiD female quadriceps that had reached the threshold of vitamin D3 toxicity. A 
242% increase in Bax/Bcl-2  (98) only corresponded to an 87% increase in cleaved/pro-
caspase 3  (99). Thus, a deficiency in vitamin D may increase the susceptibility of motor 
neurons to apoptosis without necessarily leading to large-scale apoptosis. Vitamin D has 
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been shown to reduce pro-apoptotic (Bax) and increase anti-apoptotic proteins (Bcl-2)  
(100). A reduction in calcium buffering capacity brought about by vitamin D deficiency 
may cause the cell to exert calcium-induced excitotoxicity, which leads to elevated levels 
of Bax/Bcl-2.  
With respect to neuron damage, both AI and DEF males had lower ChAT (23% 
and 22%, respectively) and SMI-32 (15% and 17%, respectively) compared to their 
female counterparts, likely due to the protective effect of estrogen in females.  In mSOD1 
mice, onset, disease progression and survival are dependent on sex; males lose body 
weight more rapidly following disease onset and die sooner than females  (101, 102). A 
reduction in body weight reflects muscle atrophy brought about by motor neuron 
degeneration. As with high motor neuron count in females, it is possible that damaged 
motor neurons are also more prevalent. This explains why SMI-36 levels were 13% lower 
in AI males vs. AI females. This can also explain why there was no difference in SMI-
36/SMI-32 ratio between AI males and AI females, as SMI-32 and SMI-36 levels were 
both lower in males vs. females.  Ultimately, neuron damage was not different between 
the diets, indicating that even though vitamin D deficiency may exacerbate disease 
pathophysiology, it does not have an impact on neuron damage.  
On a tissue level, there was no significant difference in body weight-adjusted 
spinal cord weights between the diets. However, a sexual dimorphism was confirmed as 
AI males and DEF males had 33% and 27% lighter body weight-adjusted spinal cord 
weight vs. their female counterparts. This may be due to the protective effects of estrogen 
in the female spinal cord. These results contrast our previous study that found no 
difference in body weight-adjusted brain weights between the diets and sexes  (103). 
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Correlational analysis showed that there was no association between body weight-
adjusted brain weights  (103) and body weight-adjusted spinal cord weights. This 
confirms that ALS pathology within the CNS is mainly localized to the spinal cord.   
This study outlines the detrimental effects of vitamin D deficiency and confirms 
the lower paw grip endurance and motor performance that was observed in our previous 
study in the same mouse model  (37).  When compared to AI mice, DEF mice had 25% 
lower paw grip endurance (PaGE) AUC and 19% lower motor performance. Between the 
sexes, AI males had lower ability to move, PaGE and motor performance compared to AI 
females. AI males also had a higher clinical score, hastened disease onset, and reached 
hind limb paralysis and endpoint faster compared to AI females. The current study 
confirms that the functional outcomes observed are linked to neuronal damage in the 
spinal cord. Previous studies on spinal cord injury (SCI) rats have shown that motor 
performance disturbance following SCI is associated with the severity of spinal cord 
pathology  (104). Damage in the spinal cord also reflects that in the quadriceps, where 
DEF female, but not male, G93A mice had higher inflammation and apoptosis as 
compared to AI females (35, 36). Despite the fact that the spinal cords of DEF females 
had higher inflammation, DEF male spinal cords were more susceptible to damage as 
marked by lower levels of SOD2 and higher levels of markers of neuron damage. We 
postulate that this is due to the protective effects of estrogen in females. The restricted 
vitamin D3 intake in this study corresponds to ~25 IU/d for an 80 kg man and ~20 IU/d 
for a 70 kg woman. These values may be insufficient for patients with ALS. Indeed, 
Karam et al’s study on ALS patients found that supplementation with 2000 IU of vitamin 
D3/day for 9 months improved ALS functional rating scale score (105). A retrospective 
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study on ALS patients found that those with serum calcidiol levels <25 nmol/L increased 
their death rate by 6 fold and their rate of decline by 4 times, and were associated with a 
marked shorter life expectancy compared to patients with serum calcidiol levels >75 
nmol/L  (33). Furthermore, Guamanian Chamorros with ALS have serum calcitriol levels 
in the low to low-normal range (17). In humans following supplementation with 10 000 
IU/d dosages in patients with MS for 12 weeks [114] and up to 40 000 IU/d for 28 weeks 
[115], ALS patients in Karam et al’s study may have shown greater improvements in 
their ALSFRS-R had they been supplemented with dosages between 10 000-40 000 IU/d. 
Based on these studies, and given our previous studies supplementing ALS mice with 10x 
and 50x AI, we restate our previous hypothesis that the optimal therapeutic vitamin D 
dosage, both functionally and cellularly, lies between 10x and 50x AI vitamin D (27, 103, 
106).  
In conclusion, the present study demonstrates that vitamin D deficiency 
exacerbates disease pathophysiology in the G93A mouse model of ALS. This is marked 
by increased inflammation and oxidative damage and lower antioxidant capacity. 
However, it is important to note that sexual dimorphism exists and that the pathways that 
vitamin D deficiency negatively impacts differ between males and females  (107).   
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SUMMARY AND FUTURE RESEARCH 
Summary 
The objective of this thesis was to determine the effects of dietary D3 
supplementation, restriction and adequate intake on oxidative damage, antioxidant 
capacity, inflammation, apoptosis, neurotrophic factor and neuron count in the spinal 
cord of the G93A mouse model of ALS.  
Oxidative damage 
Oxidative damage was increased in HiD females, indicating the presence of 
vitamin D toxicity. This was observed by 14% higher 3-NY protein content in HiD 
females vs. AI females. However, at non-toxic levels, vitamin D can lower 3-NY 
production by lowering the formation of NO products and increasing p53 protein, which 
aids in DNA repair (230). This explains why HiD males had 16% lower 3-NY protein 
content compared to HID females. In females, non-toxic vitamin D levels, combined with 
estrogen’s ability to directly inhibit NOS activity, reduces peroxynitrite and subsequently 
3-NY generation  (231). This is why AI males had 18% higher 3-NY protein content vs. 
AI females.  
A deficiency in vitamin D reduces the amount of calcium buffering protein, 
further dysregulating calcium homeostasis, producing ROS and thus leading to higher 
lipid peroxidation (232). In females, estrogen can protect the from cell lipid peroxidation 
as co-exposure of 17β-estradiol and 4-HNE in PC12 cell lines showed that estrogen was 
significantly effective against the cytotoxic response of 4-HNE  (233).  As males lack 
high levels of estrogen, DEF males had 23% higher 4-HNE protein content vs. AI males 
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whereas DEF females did not exhibit any significant changes in their 4-HNE protein 
levels.   
Antioxidant Capacity 
In HiD females, excessive inflammation resulted in a 21% decrease in catalase 
compared to AI females (P < 0.001). This pattern is supported by studies on rat liver, 
where TNF- α, a marker of inflammation, suppresses protein expression of both catalase 
and peroxisomal proteins (234).  However, Gpx1, a protective antioxidant with similar 
function as catalase was 18% higher in HiD females vs. AI females. Contrary to catalase, 
toxicity results in an adaptive increase in GPx1 levels to compensate for the elevated 
cellular damage. Physiologically, vitamin D has an inverse relationship with GPx1 and a 
positive association GR activity  (235) in order to maintain high GSH concentrations, a 
regulator of intracellular redox balance. However, under vitamin D toxicity, excessive 
oxidative damage likely surpasses vitamin D’s ability to efficiently regulate GPx1 which 
results in an adaptive increase in GPx1 levels.  The 10% higher GPx1 levels in AI males 
vs. AI females indicates that at adequate, non-toxic levels, vitamin D reduces GPx1 in 
females vs. males, also indicating that there is lower cellular damage occurring in AI 
females vs. AI males. 
In vitamin D deficiency, excessive inflammation in DEF females vs. AI females, 
as reflected by high IL-6 levels, resulted in a compensatory increase GPx1 activity  (236). 
This further confirms that high GPx1 protein levels are an indicator of elevated 
intracellular oxidative damage and inflammation.  In DEF males, SOD2 was 18% higher 
than in AI males. In ALS, activated microglia use the NF-κB pathway to induce 
mitochondrial dysfunction inhibition of SOD2 and motor neuron death  (237, 238). NF-
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κB leads to mitochondrial dysfunction inhibition of SOD2 by activating iNOS  (239). 
iNOS releases high amounts of NO, which react with superoxide to generate the 
peroxynitrite necessary  (240), to cease enzymatic activity and produce 3-NY  (241). The 
local conversion of calcidiol to calcitriol in the CNS is a neuroprotective response that 
inhibits NF-κB-related iNOS induction (242). Without the protective effects of vitamin 
D, this neuroprotection diminishes, which may explain the lower levels of SOD2 in DEF 
males. 
Inflammation 
HiD females had 21% higher TNF- α levels and 13% lower anti-inflammatory 
cytokine IL-10 compared to AI females. This indicates that a more inflammatory milieu 
is present in HiD females, likely due to the excessive oxidative stress brought about by 
hypervitaminosis D. High TNF- α/IL-10 ratio has been observed in the renal tissue of rats 
with systematic inhibition of NOS  (243), resulting in lower NO production, lowering IL-
10 levels and increasing TNF- α levels (243). The 11% lower IL-10 protein content in AI 
males compared to AI females may be an indicator that oxidative damage is higher in 
males, confirmed by higher 3-NY levels. Hence NOS inhibition is higher in males vs. 
females. At non-toxic levels, as observed in HiD males, inflammation, marked by IL-6 
levels, was 24% lower compared to AI males. 800 IU/d vitamin D3 supplementation in 
colorectal adenoma patients showed a 32% decrease in plasma IL-6 levels  (244). As 
well, testosterone exerts a strong anti-inflammatory effect by lowering IL-6 levels  (245-
247) observed by AI and HiD males having 14% and 38% lower IL-6 levels compared to 
their female counterparts, respectively. 
 142 
The anti-inflammatory effect of testosterone was also observed in DEF males as 
they had 29% lower IL-6, vs. DEF females. In DEF females, IL-6 levels were 22% higher 
vs. AI females. Contrary to testosterone; estrogen promotes IL-6 production and release 
during cellular damage (248). Without vitamin D’s anti-inflammatory properties, a 
deficiency during trauma puts women, the sex that naturally possesses high levels of IL-
6, at a greater risk of elevated levels of the inflammatory cytokine  (249). Our findings 
are in accord with Miller et al’s study that showed that women with serum 25(OH)D 
levels of <37.5 nmol/L at the time of hip fracture, indicative of cellular damage, had 
higher serum IL-6 levels in the year after the hip fracture (249).  
Apoptosis  
HiD females had 13% higher cleaved/pro-caspase 3 ratio compared to AI females 
due to a 15% increase in cleaved caspase 3. In HiD females, elevated 3-NY levels 
indicate the presence of oxidative stress which can activate caspase 3 in the spinal cord of 
mSOD1 mice (250).  Because males did not reach the threshold of toxicity, vitamin D 
had a protective role in males as the HiD group had a 26% lower cleaved/pro-caspase 3 
ratio compared to AI males. Vitamin D has been shown to reduce activated caspase 3 in 
the spinal cord of EAE mice  (251). In HiD males, the downregulation of microglial 
activation, and thus oxidative damage and inflammation, may have resulted in reduction 
of apoptosis.  
In DEF mice, vitamin D no longer exerted its protective effects and thus bax/bcl-2 
ratio was elevated by 23% in DEF mice vs. AI. A reduction in calcium buffering capacity 
brought about by vitamin D deficiency may cause the cell to exert calcium-induced 
excitotoxicity, which leads to elevated levels of bax/bcl-2. However, this increase was 
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not sufficient enough to activate caspase 3, the effector molecule in the apoptotic 
pathway. This is also confirmed in our previous study in HiD female quadriceps where a 
242% increase in bax/bcl-2  (252) only corresponded to an 87% increase in cleaved/pro-
caspase 3  (229). Thus, a deficiency in vitamin D may increase the susceptibility of motor 
neurons to apoptosis without necessarily leading to large-scale apoptosis.  
Neurotrophic Factor 
There was no significant difference in GDNF protein content between the diets 
and sexes in both HiD and DEF groups.  
Neuron Damage 
HiD females had 18% lower ChAT compared to AI females. This may be due to higher 
peroxynitrite levels, marked by increased 3-NY levels, which inhibits acetylcholine 
synthesis  (253). AI males had 23% lower ChAT and 15% lower SMI-32 compared to AI 
females, indicating higher neuron damage. In mSOD1 mice, onset, disease progression 
and survival are dependent on sex; males lose body weight more rapidly following 
disease onset and die before females (254, 255) A reduction in body weight is reflective 
of muscle atrophy brought about by neuron degeneration. As with increased motor 
neuron count in AI females, it is more likely that damaged motor neurons are also more 
prevalent. This explains why SMI-36 levels were 13% lower in AI males vs. AI females. 
Despite lower motor neurons in HiD males vs. HiD females, they had 19% lower SMI-
36/SMI-32 ratio, a proxy measure of motor neuron loss  (256), compared to AI males. 
With lower apoptosis, it is evident that motor neuron integrity is maintained, and a 
decrease in SMI-36/SMI-32 ratio is evident. 
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DEF males also had 22% lower ChAT and 17% lower SMI-32 compared to their 
female counterparts, likely due to the protective effect of estrogen in females. This 
pattern is also retained in AI males vs. AI females, indicating the presence of a sexual 
dimorphism due to sex hormones. Because there was no change in neuron count between 
the diets, our findings confirm that though vitamin D deficiency may exasperate disease 
pathophysiology, it does not have an impact on neuron count.  
Future Research 
 
Future research need to measure the effect of D3 supplementation and restriction 
tested in this thesis on markers related to mechanisms implicated in ALS 
pathophysiology. Markers of oxidative damage (4-HNE and 3-NY), antioxidant capacity 
(SOD2, catalase and GPx1), inflammation (TNF-α, IL-6, IL-10), apoptosis (caspase 3, 
BAX and Bcl-2), neurotrophic factor (GDNF) and neuron count (SMI-32/SMI-36) need 
to be measured in the brain to confirm if they follow a pattern similar to what was 
observed in the spinal cord.  
As well, recent studies have focused on the role of endoplasmic reticulum (ER) 
stress in ALS pathology (252, 257). Dysregulated calcium homeostasis and oxidative 
stress can damage the ER, the organelle responsible for protein synthesis, folding and 
targeting. Studies in G93A quadriceps confirmed that vitamin D deficiency reduces 
calcium-buffering capacity and increases prolonged ER-stress-induced apoptosis in 
females  (257). On the contrary, D3 supplementation at 50x AI decreases ER stress in 
females  (252). ER stress has also been observed in the spinal cord of ALS patients, 
where it is linked to protein damage, aggregation, at increased motor neuron death (258). 
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Thus, future studies should focus how vitamin D restriction and supplementation impacts 
the ER within the spinal cord, focusing on markers of intracellular calcium trafficking 
(parvalbumin, calretinin, calbindin d28k) and ER stress (SERCA, CHOP).   
Lastly, vitamin D status and corresponding calcium concentrations should be 
measured to establish levels at which toxicity is induced in females, and to compare these 
levels with males. A therapeutic optimal dose of D3 also needs to be established 
concerning its effects on disease pathophysiology in this model. This is accomplished by 
examining differential doses of D3. Since 50 IU/g feed is likely the approximate threshold 
for D3 toxicity and 10x has produced beneficial results without toxic effects, we would 
recommend future experimental HiD doses to be between these amounts.    
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APPENDIX A 
 A PRIORI HYPOTHESES AND REPRESENTATIVE WESTERN BLOT BANDS 
FOR MANUSCRIPT # 1: 
 
Vitamin D3 at 50X the adequate intake attenuates disease pathophysiology in the spinal 
cord of the male, but is toxic in female, G93A mouse model of amyotrophic lateral 
sclerosis 
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Table S1.1 Rationale for establishing a priori hypotheses 
Outcome Biomarker Model 
Used 
 
Rationale for establishing a priori hypotheses 
    Male Female 
Oxidative 
Damage 
3-nitrotyrosine (3-NY) Mice and 
Human 
Quadriceps of 50x AI (HiD) G93A mice did not show significant difference 
vs. AI  (239) 
4-Hydroxynonenal (4-
HNE) 
Mice Quadriceps of 50x AI (HiD) G93A mice did not show significant difference 
vs. AI  (239) 
Antioxidant 
Enzymes 
Superoxide Dismutase 
2 (SOD2) 
Mice and 
Rats  
-Quadriceps of 50x AI (HiD) G93A mice 
showed 13% increase vs. AI (P = 0.15)  
(239) 
-Adult male diabetic Wistar rats 
supplemented with 5000 IU/kg body 
weight of 1α,25(OH)2VD3 showed 207% 
increase vs. control  (236) 
-Quadriceps of 50x AI (HiD) 
female G93A mice showed 
27% increase vs. AI (P = 
0.10)  (239) 
 
Catalase Mice and 
Rats 
-Quadriceps of 50x AI (HiD) G93A mice 
showed 13% increase vs. AI (P = 0.07)  
(239) 
-Adult male diabetic Wistar rats 
supplemented with 5000 IU/kg body 
weight of 1α,25(OH)2VD3 showed 52% 
increase vs. control  (236) 
Quadriceps of 50x AI (HiD) 
female G93A mice showed 
15% increase vs. AI (P = 
0.11)  (239) 
 
Glutathione 
Peroxidase (GPx1) 
Rats 
Adult male diabetic Wistar rats 
supplemented with 5000 IU/kg body 
weight of 1α,25(OH)2VD3 showed 72% 
increase vs. control  (236) 
 
Inflammation 
Tumour Necrosis 
Factor Alpha (TNF-α) 
Mice and 
Human 
-Quadriceps of 50x AI (HiD) G93A mice did not show significant 
difference vs. AI  (239) 
-Serum levels of patients with congestive heart failure (CHF) supplemented 
with 50 µg vitamin D(3)/d plus 500 mg Ca/d inhibited rise  (223) 
Interleukin-6 (IL-6) Mice Quadriceps of 50x AI (HiD) G93A mice did not show significant difference 
vs. AI  (229) 
Inerleukin-10 (IL-10) Human 
Serum levels of patients with congestive heart failure (CHF) supplemented 
with 50 mug vitamin D(3)/d plus 500 mg Ca/d showed 43% increase vs. 
placebo  (223) 
Apoptosis 
Bax/Bcl-2 ratio Mice  
Quadriceps of 50x AI (HiD) 
female G93A mice showed 
242% increase vs. AI (P = 
0.080)  (238) 
Pro/cleaved Caspase 3 
(CASP3) ratio 
Mice  
Quadriceps of 50x AI (HiD) 
female G93A mice showed 
87% increase vs. AI (P = 
0.084)  (229) 
Neurotrophic 
Factor 
Glial cell-derived 
Neurotrophic factor 
(GDNF) 
Rats 
Adult male Sprague–Dawley rats injected 
with 8 day pretreatment of 1 mg/kg/day 
1,25(OH)2 had 2 fold increase vs. control  
(163) 
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Table S1.2 Summary of a priori hypotheses and corresponding supporting studies  
 
Outcome 
 
Biomarkers 
 
HiD vs. AI 
 
Source 
   Male 
 
Female  
Oxidative Damage 
 
3-nitrotyrosine (3-NY) ↓ ↓ 
 (211, 229, 
239) 
 
4-hydroxynonenal (4-HNE) ↓ ↓ 
 (239, 243, 
244) 
Antioxidant 
Enzymes 
 
SOD2 ↑ ↓ 
 (236, 239, 
244) 
 
Catalase ↑ ↓ 
 (236, 239, 
244) 
 
Glutathione Peroxidase (GPx) ↑ ↑ 
 (236, 239, 
244) 
Inflammation 
 
Tumour Necrosis Factor Alpha 
(TNF-α) 
↓ ↑  (223) 
 
Interleukin-6 (IL-6) ↓ ↑  (229) 
Inerleukin-10 (IL-10) ↑ ↓  (223) 
Neurotrophic 
Factor 
Glial cell-derived neurotrophic 
factor (GDNF) ↑ ↑ 
 (163) 
 
Brain derived neurotrophic factor 
(BDNF) ↑ ↑  (163) 
Apoptosis 
Bax/Bcl-2 ratio ↓ ↑  (229, 245) 
Pro/cleaved Caspase 3 (CASP3) 
ratio ↓ ↑  (229) 
Neuron Count 
SMI-36/SMI-32 ratio ↓ ↑  (229, 238, 245) 
Choline Acetyltransferase (ChAT) ↑ ↓  (229, 238, 245) 
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Figure S1.1 Figure S1. Western blot representative bands for markers of oxidative 
damage, antioxidant enzymes, inflammation, apoptosis, neurotrophic factor and 
neuron damage. Representative immunoblots of 4-HNE, 3-NY, SOD2, catalase, GPx1, 
TNF-α, IL-6, IL-10, Bax, Bcl-2, pro-caspase 3, cleaved caspase 3, GDNF, ChAT, SMI-
32 and SMI-36 protein expression in the spinal cord of 41 G93A mice: 23 adequate 
vitamin D3 intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 18 high vitamin D3 intake (HiD; 
50 IU D3/g feed; 10 M, 8 F).  Protein intensity was standardized to GAPDH.  
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APPENDIX  B 
 A PRIORI HYPOTHESES AND WESTERN BLOT REPRESENTATIVE BANDS 
FOR MANUSCRIPT # 2: 
 
Dietary D3 restriction exacerbates disease pathophysiology in the spinal cord of the 
G93A mouse model of amyotrophic lateral sclerosis 
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Table S2.1 Rationale for establishing a priori hypotheses 
Outcome Biomarkers Model 
Used 
Rationale for establishing a priori hypotheses 
    Male  Female 
Oxidative 
Damage 
3-nitrotyrosine (3-
NY) 
Mice 
and 
Human 
-Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
-Obese children who had serum 25(OH)D levels <20 
ng/mL (DEF) had a 55% increase vs. obese children 
with serum levels ≥20 ng/mL  (211) 
 4-Hydroxynonenal 
(4-HNE) 
Mice -Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
 
Antioxidant 
Enzymes 
SOD2 Mice 
and Rats 
-Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
 Catalase Mice 
and Rats 
Quadriceps of 2.5% AI (DEF) male G93A mice 
showed 32% increase vs. AI (P = 0.009)  (244) 
Glutathione 
Peroxidase (GPx1) 
Rats -Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
 
Inflammation 
Tumour Necrosis 
Factor Alpha (TNF-
α) 
Mice 
and 
Human 
-Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
 Interleukin-6 (IL-6) Mice -Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (243) 
Inerleukin-10 (IL-10) Human 
-IL-10 were significantly higher in individuals with 
deficient (<25 nmol/L) serum 25(OH)D compared 
with those with sufficient (>75 nmol/L) status after 
adjustment for age, sex, and body mass index (P < 
.05)  (356) 
 
Neurotrophic 
Factor 
Glial cell-derived 
Neurotrophic factor 
(GDNF) 
Rats  
Offspring of Female Sprague-Dawley rats 
that were fed D3-free diet had decreased 
serum D3 levels (<35 nmol/L) and lower free 
NGF and GDNF levels by 17 and 25% 
respectively, compared to controls (P < 0.05)  
(357) 
Apoptosis 
Bax/Bcl-2 ratio Mice  
Quadriceps of 2.5% AI (DEF) female G93A 
mice showed 103% increase vs. AI (P = 
0.057)  (245) 
Pro/cleaved Caspase 
3 (CASP3) ratio 
Mice 
-Quadriceps of 2.5% AI (DEF) G93A mice did not 
show significant difference vs. AI  (244) 
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Table S2.2 Summary of a priori hypotheses and corresponding supporting studies  
Outcome Biomarkers DEF vs. AI Source 
  Male Female  
Oxidative 
Damage 
3-nitrotyrosine (3-NY) ↑ ↑  (211, 229, 239, 
244) 
4-hydroxynonenal (4-HNE) ↑ ↑  (239, 243, 
244) 
Antioxidant 
Enzymes 
SOD2 ↑ ↑  (236, 239, 
244) 
Catalase ↑ ↑  (236, 239, 
244) 
Glutathione Peroxidase (GPx) ↑ ↑  (236, 239, 
244) 
Inflammation 
Tumour Necrosis Factor Alpha 
(TNF-α) 
↑ ↑  (223) 
Interleukin-6 (IL-6) ↑ ↑  (229) 
Inerleukin-10 (IL-10) ↓ ↓  (223) 
Neurotrophic 
Factor 
Glial cell-derived neurotrophic 
factor (GDNF) 
↓ ↓ 
 (163) 
 
Brain derived neurotrophic factor 
(BDNF) 
↓ ↓  (163) 
Apoptosis 
Bax/Bcl-2 ratio ↑ ↑  (229, 245) 
Pro/cleaved Caspase 3 (CASP3) 
ratio 
↑ ↑  (229) 
Neuron Count 
SMI-36/SMI-32 ratio ↑ ↑  (229, 238, 
245) 
Choline Acetyltransferase (ChAT) ↓ ↓  (229, 238, 
245) 
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Figure S2.1 Western blot representative bands for markers of oxidative damage, 
antioxidant enzymes, inflammation, apoptosis, neurotrophic factor and neuron 
damage. Representative immunoblots of 4-HNE, 3-NY, SOD2, catalase, GPx1, TNF-α, 
IL-6, IL-10, Bax, Bcl-2, pro-caspase 3, cleaved caspase 3, GDNF, ChAT, SMI-32 and 
SMI-36 protein expression in the spinal cord of 42 G93A mice: 23 adequate vitamin D3 
intake (AI; 1 IU D3/g feed; 12 M, 11 F) and 19 deficient vitamin D3 intake (DEF; 0.025 
IU D3/g feed; 10 M, 9 F).  Protein intensity was standardized to GAPDH. 
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APPENDIX  C 
EXTENDED WESTERN BLOT METHODOLOGY FOR MANUSCRIPT #1 AND 
#2  
 181 
Western Blot  
Oxidative damage 
4-Hydroxynonenal (4-HNE) 
Spinal cord samples were prepared by loading 30 µg of protein to sample buffer 
and de-ionized water. Samples were heated for 5 min on a heating block and then size-
separated along with a protein ladder (GE Healthcare, RPN 800E) by a 12.5% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) set at 120 v (Bio-Rad, 
164-5052, Mississauga, Ontario) for ~1.5 h. Gels were then transferred to nitrocellulose 
membranes (#165-3322, Bio-Rad Mini-PROTEAN 2 electrophoresis system, 
Mississauga, ON, Canada) at 100 V for 2 h. Membranes were visualized with ponceau 
stain (Biobasic, 6226795, Mississauga, Ontario) to ensure proper transfer. Membranes 
were then blocked with 5% bovine serum albumin (BSA) (Bioshop, ALB001.500, 
Burlington, Ontario) diluted in TBST for 2 h at room temperature (RT) while shaking. 
After the block, membranes were washed 4 times for 5 min each with TBST at RT while 
shaking. Membranes were incubated with rabbit polyclonal primary antibody against 4-
hydroxynonenal (4-HNE; Abcam, ab46545) at a dilution of 1/800 in 5% BSA diluted in 
TBST overnight (18 h) at 4°C while shaking. Membranes were washed 4 times for 5 min 
each and the antigen-antibody complexes were detected by incubating the membrane 
with goat anti-mouse HRP conjugated secondary antibody at a dilution of 1/5000 (Novus 
Biologicals, NB7539) in 5% fat free milk diluted in TBST for 2 h at RT. Immunoreactive 
proteins were visualized with enhanced chemiluminescence (ECL) (Santa Cruz 
Biotechnology, SC-2048) and exposed to Kodak autoradiographic film. Films were 
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scanned and the protein intensity was standardized to GAPDH using Carestream MI (v 
5.0.2.30, NY, USA). 
3-Nitrotyrosine  
Protein damage was analyzed by measuring 3-NY protein content using the same 
protocol as 4-HNE but with the following modifications: 30 µg of protein was used; 
membranes were blocked in 5% BSA diluted in TBST for 1 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with 
mouse monoclonal primary antibody against 3-nitrotyrosine (3-NY; Abcam, ab110282) 
at a dilution of 1/1000 in 5% BSA diluted in TBST overnight (18 h) at 4°C while 
shaking; membranes were washed (4 x 5 min) using TBST and then incubated with goat 
anti-mouse HRP conjugated secondary antibody (Novus Biologicals, NB7539) at a 
dilution of 1/5000 in 5% BSA diluted in TBST for 2 h at RT. The protein adducts form 
on several proteins of different molecular weights. Thus, protein intensity of the entire 
column was determined by summing the area under the curve for all peaks within the 
column (12-225 kDa). Films were scanned and the protein intensity was standardized to 
GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
Antioxidant Enzymes 
Superoxide Dismutase 2 (SOD2) 
SOD2 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 5 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 31 kDa to identify SOD2 (25 kDa); 
membranes were blocked in 5% fat free milk diluted in TBST for 2 h at RT while 
shaking; membranes were washed (4 x 5 min) using TBST; membranes were incubated 
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with rabbit polyclonal primary antibody against superoxide dismutase 2 (SOD2; Abcam, 
ab13533) at a dilution of 1/2000 in 1% BSA diluted in TBST overnight (18 h) at 4°C 
while shaking; membranes were washed (4 x 5 min) using TBST and then incubated with 
goat anti-rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a 
dilution of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were scanned 
and the protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, 
NY, USA). 
Catalase 
Catalase protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 15 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 31 kDa to identify catalase (60 kDa); 
membranes were blocked in 5% fat free milk diluted in TBST for 2 h at RT while 
shaking; membranes were washed (4 x 5 min) using TBST; membranes were incubated 
with rabbit polyclonal primary antibody against catalase (Abcam, ab1877-10) at a 
dilution of 1/3500 in 5% fat free milk diluted in TBST overnight (18 h) at 4°C while 
shaking; membranes were washed (4 x 5 min) using TBST and then incubated with goat 
anti-rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a 
dilution of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were scanned 
and the protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, 
NY, USA). 
Glutathione Peroxidase 1 (GPx1) 
GPx1 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 20 µg of protein was used; membranes were 
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visualized with ponceau stain and were cut at 31 kDa to identify GPx1 (22 kDa); 
membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with rabbit 
polyclonal primary antibody against glutathione peroxidase 1 (GPx1; Abcam, ab22604) 
at a dilution of 1/800 in 5% BSA diluted in TBST overnight (18 h) at 4°C while shaking; 
membranes were washed (4 x 5 min) using TBST and then incubated with goat anti-
rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a dilution 
of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were scanned and the 
protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, 
USA). 
Inflammation 
Tumor necrosis factor α (TNF- α) 
TNF- α protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 35 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 31 kDa  to identify TNF- α (17 kDa); 
membranes were blocked in 5% fat free milk diluted in TBST for 2 h at RT while 
shaking; membranes were washed (4 x 5 min) using TBST; membranes were incubated 
with rabbit polyclonal primary antibody against tumor necrosis factor α (TNF- α; Abcam, 
ab9739) at a dilution of 1/2000 in 5% fat free milk diluted in TBST overnight (18 h) at 
4°C while shaking; membranes were washed (4 x 5 min) using TBST and then incubated 
with goat anti-rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) 
at a dilution of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were 
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scanned and the protein intensity was standardized to GAPDH using Carestream MI (v 
5.0.2.30, NY, USA). 
Interleukin-6 (IL-6) 
IL-6 protein content was measured via WB using the same protocol as 4-HNE but 
with the following modifications: 20 µg of protein was used; membranes were visualized 
with ponceau stain and were cut at 31 kDa to identify IL-6 (band between 21-28 kDa); 
membranes were blocked in 5% fat free milk diluted in TBST for 2 h at RT while 
shaking; membranes were washed (4 x 5 min) using TBST; membranes were incubated 
with rabbit polyclonal primary antibody against interleukin-6 (IL-6; Abcam, ab6672) at a 
dilution of 1/1000 in 5% fat free milk diluted in TBST overnight (18 h) at 4°C while 
shaking; membranes were washed (4 x 5 min) using TBST and then incubated with goat 
anti-rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a 
dilution of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were scanned 
and the protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, 
NY, USA) 
Interleukin-10 (IL-10) 
IL-10 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 10 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 31 kDa to identify IL-10 (20 kDa); 
membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were then incubated with 
rabbit polyclonal primary antibody against interleukin-10 (IL-10; Abcam, ab9969) at a 
dilution of 1/2000 in 3% BSA overnight (18 h) at 4°C while shaking; membranes were 
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washed (4 x 5 min) using TBST and then incubated with goat anti-rabbit HRP conjugated 
secondary antibody (Novus Biologicals, NB730-H) at a dilution of 1/5000 in 3% BSA 
diluted in TBST for 2 h at RT. Films were scanned and the protein intensity was 
standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
Apoptosis 
Bcl-2-associated X protein (Bax) 
Bax protein content was measured via WB using the same protocol as 4-HNE but 
with the following modifications: 25 µg of protein was used; membranes were visualized 
with ponceau stain and were cut at 31 kDa  to identify TNF- α (20 kDa); membranes 
were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; membranes were 
washed (4 x 5 min) using TBST; membranes were incubated with rabbit polyclonal 
primary antibody against Bax (Cell Signaling Technology, 2772) at a dilution of 1/1000 
in 5% BSA diluted in TBST overnight (18 h) at 4°C while shaking; membranes were 
washed (4 x 5 min) using TBST and then incubated with goat anti-rabbit HRP conjugated 
secondary antibody (Novus Biologicals, NB730-H) at a dilution of 1/4000 in 5% BSA 
diluted in TBST for 2 h at RT. Films were scanned and the protein intensity was 
standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
B-cell lymphoma 2 (Bcl-2) 
Bcl-2 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 25 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 31 kDa to identify Bcl-2 (17 kDa); 
membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with rabbit 
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polyclonal primary antibody against Bcl-2 (Cell Signaling Technology, 2870) at a 
dilution of 1/1000 in 5% BSA diluted in TBST overnight (18 h) at 4°C while shaking; 
membranes were washed (4 x 5 min) using TBST and then incubated with goat anti-
rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a dilution 
of 1/5000 in 5% BSA diluted in TBST for 2 h at RT. Films were scanned and the protein 
intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
Pro-caspase 3 
Pro-caspase 3 protein content was measured via WB using the same protocol as 4-
HNE but with the following modifications: 20 µg of protein was used; membranes were 
blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; membranes were 
washed (4 x 5 min) using TBST; membranes were incubated with rabbit polyclonal 
primary antibody against pro-caspase 3 (Millipore 04-440) at a dilution of 1/1000 in 5% 
BSA diluted in TBST overnight (18 h) at 4°C while shaking; membranes were washed (4 
x 5 min) using TBST and then incubated with goat anti-rabbit HRP conjugated secondary 
antibody (Novus Biologicals, NB730-H) at a dilution of 1/5000 in 5% BSA diluted in 
TBST for 2 h at RT. Membranes were scanned and the protein intensity was standardized 
to GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
Cleaved caspase 3 
Cleaved caspase 3 protein content was measured via WB using the same protocol 
as 4-HNE but with the following modifications: 25 µg of protein was used; membranes 
were visualized with ponceau stain and were cut at 31 kDa to identify cleaved caspase 3 
(17 kDa); membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while 
shaking; membranes were washed (4 x 5 min) using TBST; membranes were incubated 
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with rabbit polyclonal primary antibody against cleaved caspase 3 (Millipore 04-439) at a 
dilution of 1/1000 in 1% BSA diluted in TBST overnight (18 h) at 4°C while shaking; 
membranes were washed (4 x 5 min) using TBST and then incubated with goat anti-
rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a dilution 
of 1/5000 in 1% BSA diluted in TBST for 2 h at RT. Films were scanned and the protein 
intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, USA). 
Neurotrophic Factor 
Glial cell-derived neurotrophic factor (GDNF) 
GDNF protein content was measured via western blot using the same protocol as 
4-HNE but with the following modifications: 25 µg of protein was used; membranes 
were visualized with ponceau stain to identify catalase (~24 kDa); membranes were 
blocked in 5% BSA diluted in TBST for 1 h at RT while shaking; membranes were 
washed (4 x 5 min) using TBST; membranes were incubated with rabbit polyclonal 
primary antibody against GDNF (Abcam, ab18956) at a dilution of 1/1000 in 1% BSA 
diluted in TBST overnight (18 h) at 4°C while shaking; membranes were washed (4 x 5 
min) using TBST and then incubated with goat anti-rabbit HRP conjugated secondary 
antibody (Novus Biologicals, NB730-H) at a dilution of 1/5000 in 1% BSA diluted in 
TBST for 2 h at RT. Films were scanned and the protein intensity was standardized to 
GAPDH using Carestream MI (v 5.0.2.30, NY, USA).. 
Neuronal Damage 
Choline acetyltransferase (ChAT) 
ChAT protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 10 µg of protein was used; membranes were 
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visualized with ponceau stain and were cut at 31 kDa  to identify ChAT (75 kDa); 
membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with rabbit 
polyclonal primary antibody against choline acetyltransferase (ChAT; Abcam, ab85609) 
at a dilution of 1/1000 in 5% fat free milk diluted in TBST overnight (18 h) at 4°C while 
shaking; membranes were washed (4 x 5 min) using TBST and then incubated with goat 
anti-rabbit HRP conjugated secondary antibody (Novus Biologicals, NB730-H) at a 
dilution of 1/5000 in 5% fat free milk diluted in TBST for 2 h at RT. Films were scanned 
and the protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, 
NY, USA). 
Neurofilament Heavy (unphosphorylated) antibody (SMI-32) 
SMI-32 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 25 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 76 kDa to identify SMI-32 (180-200 kDa); 
membranes were blocked in 5% BSA diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with 
mouse monoclonal primary antibody against SMI-32 (Abcam, ab28029) at a dilution of 
1/1000 in 3% BSA diluted in TBST overnight (18 h) at 4°C while shaking; membranes 
were washed (4 x 5 min) using TBST and then incubated with anti-mouse HRP 
conjugated secondary antibody against SMI-32 (Novus Biologicals, NB7539) at a 
dilution of 1/5000 in 3% milk diluted in TBST for 2 h at RT. Films were scanned and the 
protein intensity was standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, 
USA) 
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Neurofilament heavy (phosphorylated) protein (SMI-36) 
SMI-36 protein content was measured via WB using the same protocol as 4-HNE 
but with the following modifications: 25 µg of protein was used; membranes were 
visualized with ponceau stain and were cut at 76 kDa to identify SMI-36 (200 kDa); 
membranes were blocked in 3% milk diluted in TBST for 2 h at RT while shaking; 
membranes were washed (4 x 5 min) using TBST; membranes were incubated with 
mouse monoclonal primary antibody against SMI-36 (Abcam, ab24572) at a dilution of 
1/1000 in 3% milk diluted in TBST overnight (18 h) at 4°C while shaking; membranes 
were washed (4 x 5 min) using TBST and then incubated with goat anti-rabbit HRP 
conjugated secondary antibody (Novus Biologicals, NB730-H) at a dilution of 1/5000 in 
3% milk diluted in TBST for 2 h at RT. Films were scanned and the protein intensity was 
standardized to GAPDH using Carestream MI (v 5.0.2.30, NY, USA) 
Loading Control 
To correct for loading differences, ponceau staining was used as well as probing for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Membranes were either cut 
between 31-52 kDa to identify GAPDH protein content (38 kDa) or re-probed using mild 
stripping buffer 
(http://www.abcam.com/ps/pdf/protocols/Stripping%20for%20reprobing.pdf). If 
membranes were re-probed, the membranes were incubated in stripping buffer twice for 
10 minutes at RT while shaking and then washed with tris-buffered saline (TBS) 2 times 
for 10 min each and subsequently in tris-buffered saline with tween (TBST) 2 times for 5 
min each. Membranes were blocked for 2 h at room temperature (RT) while shaking. 
They were then washed in TBST 4 times for 5 min each. The membranes were then 
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incubated with mouse monoclonal primary antibody against GAPDH (Millipore, 
MAB374) at a dilution of 1:100 000 overnight (18 h) at 4˚C while shaking. Membranes 
were then washed with TBST 4 times for 5 min each. The antigen-antibody complexes 
were detected by incubating the membrane with anti-mouse HRP conjugated secondary 
antibody at a dilution of 1/5000 (Novus Biologicals, NB7539). Films were scanned and 
the protein intensity was measured using Carestream MI (v 5.0.2.30, NY, USA). 
 
 
 
 
